SLXP Документы SEC - Salix Therapeuticals, Inc.- Годовой отчет, доверенное заявление, проспект эмиссии

Основная статистика

CIK

1009356

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Salix Therapeuticals, Inc.

SEC Filings (Chronological Order)

На этой странице представлен полный хронологический список документов SEC, за исключением документов о собственности, которые мы предоставляем в других местах.

April 13, 2015	15-12G	Salix Therapeuticals 15-12G 15-12G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 000-23265 Salix Pharmaceuticals, Ltd. (Exact name of registrant as sp
April 13, 2015	15-12G	Salix Therapeuticals FORM 15-12G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 000-23265 Salix Pharmaceuticals, Ltd. (Exact name of registrant as specified
April 2, 2015	RW	Salix Therapeuticals RW RW Salix Pharmaceuticals, Inc. Oceana Therapeutics, Inc. Santarus, Inc. c/o Salix Pharmaceuticals, Ltd. 8510 Colonnade Center Drive Raleigh, North Carolina 27615 April 2, 2015 Via EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-3628 RE: Salix Pharmaceuticals, Ltd. Registration Statement on Form S-4 (File No. 333-19642
April 1, 2015	S-8 POS	Salix Therapeuticals S-8 POS S-8 POS As filed with the Securities and Exchange Commission on April 1, 2015 Registration No.
April 1, 2015	EX-3.2	BY-LAWS SALIX PHARMACEUTICALS, LTD. ARTICLE I EX-3.2 Exhibit 3.2 BY-LAWS OF SALIX PHARMACEUTICALS, LTD. ARTICLE I Stockholders Section 1.1. Annual Meetings. An annual meeting of stockholders shall be held for the election of directors at such date, time and place either within or without the State of Delaware, or may not be held at any place, but may instead be held solely by means of remote communication, as may be designated by the Board of
April 1, 2015	EX-4.2	FIRST SUPPLEMENTAL INDENTURE EX-4.2 5 d902767dex42.htm EX-4.2 Exhibit 4.2 FIRST SUPPLEMENTAL INDENTURE FIRST SUPPLEMENTAL INDENTURE (this “Supplemental Indenture”), dated as of April 1, 2015, between Salix Pharmaceuticals, Ltd., a Delaware corporation, as issuer (the “Company”) and U.S. Bank National Association, as trustee (in such capacity, the “Trustee”). W I T N E S S E T H WHEREAS, the Company has heretofore executed and
April 1, 2015	S-8 POS	Salix Therapeuticals S-8 POS S-8 POS As filed with the Securities and Exchange Commission on April 1, 2015 Registration No.
April 1, 2015	POSASR	Salix Therapeuticals POSASR POSASR As filed with the Securities and Exchange Commission on April 1, 2015 Registration No.
April 1, 2015	EX-4.1	FIRST SUPPLEMENTAL INDENTURE EX-4.1 Exhibit 4.1 FIRST SUPPLEMENTAL INDENTURE FIRST SUPPLEMENTAL INDENTURE (this ?Supplemental Indenture?), dated as of April 1, 2015, between Salix Pharmaceuticals, Ltd., a Delaware corporation, as issuer (the ?Company?) and U.S. Bank National Association, as trustee (in such capacity, the ?Trustee?). W I T N E S S E T H WHEREAS, the Company has heretofore executed and delivered to the Trustee
April 1, 2015	S-8 POS	Salix Therapeuticals S-8 POS S-8 POS As filed with the Securities and Exchange Commission on April 1, 2015 Registration No.
April 1, 2015	S-8 POS	Salix Therapeuticals S-8 POS S-8 POS As filed with the Securities and Exchange Commission on April 1, 2015 Registration No.
April 1, 2015	S-8 POS	Salix Therapeuticals S-8 POS S-8 POS As filed with the Securities and Exchange Commission on April 1, 2015 Registration No.
April 1, 2015	EX-99.25	EX-99.25 slxp-form25
April 1, 2015	EX-99.A.5.XIII	VALEANT PHARMACEUTICALS INTERNATIONAL, INC. COMPLETES TENDER OFFER FOR SALIX PHARMACEUTICALS, LTD. EX-99.A.5.XIII Exhibit (a)(5)(xiii) International Headquarters 2150 St. Elz?ar Blvd. West Laval, Quebec H7L 4A8 Phone: 514.744.6792 Fax: 514.744.6272 Contact Information: Laurie W. Little Valeant Pharmaceuticals International, Inc. 949-461-6002 [email protected] Media: Renee E. Soto/Meghan Gavigan Sard Verbinnen & Co. 212-687-8080 [email protected] / [email protected] VALEANT PHARMACE
April 1, 2015	SC TO-T/A	Valeant Pharmaceuticals International SC TO-T/A SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (RULE 14d-100) Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 9) Salix Pharmaceuticals, Ltd. (Name of Subject Company (Issuer)) Sun Merger Sub, Inc. a wholly owned subsidiary of Valeant Pharmaceuticals International a wholly owned subs
April 1, 2015	RW	Salix Therapeuticals RW RW Salix Pharmaceuticals, Ltd. 8510 Colonnade Center Drive Raleigh, North Carolina 27615 April 1, 2015 Via EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-3628 RE: Salix Pharmaceuticals, Ltd. Registration Statement on Form S-4 (File No. 333-196425) Ladies and Gentlemen: Pursuant to Rule 477 under the Securities Act of
April 1, 2015	S-8 POS	Salix Therapeuticals S-8 POS S-8 POS As filed with the Securities and Exchange Commission on April 1, 2015 Registration No.
April 1, 2015	EX-99.1	Redemption of All of Salix’s Outstanding 6.00% Senior Notes due 2021 EX-99.1 Exhibit 99.1 International Headquarters 2150 St. Elz?ar Blvd. West Laval, Quebec Canada H7L 4A8 Phone: 514.744.6792 Fax: 514.744.6272 Contact Information: Laurie W. Little 949-461-6002 [email protected] Redemption of All of Salix?s Outstanding 6.00% Senior Notes due 2021 LAVAL, QUEBEC, April 1, 2015 ? Salix Pharmaceuticals, Ltd. (?Salix?), a wholly owned subsidiary of Valeant Pharm
April 1, 2015	S-8 POS	Salix Therapeuticals S-8 POS S-8 POS As filed with the Securities and Exchange Commission on April 1, 2015 Registration No.
April 1, 2015	S-8 POS	Salix Therapeuticals S-8 POS S-8 POS As filed with the Securities and Exchange Commission on April 1, 2015 Registration No.
April 1, 2015	S-8 POS	Salix Therapeuticals S-8 POS As filed with the Securities and Exchange Commission on April 1, 2015 Registration No.
April 1, 2015	POSASR	Salix Therapeuticals POSASR POSASR As filed with the Securities and Exchange Commission on April 1, 2015 Registration No.
April 1, 2015	S-8 POS	Salix Therapeuticals S-8 POS S-8 POS As filed with the Securities and Exchange Commission on April 1, 2015 Registration No.
April 1, 2015	SC 14D9/A	Salix Therapeuticals SC 14D9/A SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Amendment No. 7) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 Salix Pharmaceuticals, Ltd. (Name of Subject Company) Salix Pharmaceuticals, Ltd. (Names of Persons Filing Statement) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Securit
April 1, 2015	S-8 POS	Salix Therapeuticals S-8 POS S-8 POS As filed with the Securities and Exchange Commission on April 1, 2015 Registration No.
April 1, 2015	8-K	Changes in Control of Registrant, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Material Modification to Rights of Security Holders, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits, Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 1, 2015 SALIX PHARMACEUTICALS, LTD.
April 1, 2015	S-8 POS	Salix Therapeuticals S-8 POS S-8 POS As filed with the Securities and Exchange Commission on April 1, 2015 Registration No.
April 1, 2015	EX-3.1	AMENDED AND RESTATED CERTIFICATE OF INCORPORATION SALIX PHARMACEUTICALS, LTD. EX-3.1 2 d902767dex31.htm EX-3.1 Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF SALIX PHARMACEUTICALS, LTD. FIRST. The name of the corporation is Salix Pharmaceuticals, Ltd. SECOND. The address of the corporation’s registered office in the State of Delaware is Corporation Service Company, 2711 Centerville Road, Suite 400 in the City of Wilmington, County of New Castle, 19808. The
April 1, 2015	S-8 POS	Salix Therapeuticals S-8 POS S-8 POS As filed with the Securities and Exchange Commission on April 1, 2015 Registration No.
March 26, 2015	EX-99.A.27	AMENDMENT TO AMENDED AND RESTATED EMPLOYMENT AGREEMENT BY AND BETWEEN SALIX PHARMACEUTICALS, INC. WILLIAM BERTRAND EX-99.A.27 2 d897658dex99a27.htm EX-99.A.27 Exhibit (a)(27) AMENDMENT TO AMENDED AND RESTATED EMPLOYMENT AGREEMENT BY AND BETWEEN SALIX PHARMACEUTICALS, INC. AND WILLIAM BERTRAND This Amendment (“Amendment”) to the Amended and Restated Employment Agreement by and between Salix Pharmaceuticals, Inc., a California corporation with its principal place of business in Wake County, North Carolina (toget
March 26, 2015	SC 14D9/A	Salix Therapeuticals SC 14D9/A SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Amendment No. 6) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 Salix Pharmaceuticals, Ltd. (Name of Subject Company) Salix Pharmaceuticals, Ltd. (Names of Persons Filing Statement) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Securit
March 26, 2015	EX-99.A.28	NONCOMPETITION AGREEMENT EX-99.A.28 3 d897658dex99a28.htm EX-99.A.28 Exhibit (a)(28) NONCOMPETITION AGREEMENT THIS NONCOMPETITION AGREEMENT (“Agreement”) shall be effective as of the 25th day of March, 2015 (the “Effective Date”) by and between Salix Pharmaceuticals, Inc., a California corporation with its principal place of business in Wake County, North Carolina (together with its subsidiaries, affiliates and successors
March 25, 2015	EX-99.D.5	Page 2 of 5 EX-99.D.5 Exhibit(d)(5) Valeant Pharmaceuticals North America LLC 400 Somerset Corporate Boulevard Bridgewater, New Jersey 08807 Tel: 908.927.1400 www.valeant.com March 24, 2015 William C. Bertrand 3056 Lewis Farm Rd Raleigh, NC 27607 Dear Bill, We are pleased to provide you with this letter as confirmation of your offer of employment with Valeant Pharmaceuticals North America LLC (?Valeant?). Thi
March 25, 2015	SC TO-T/A	Valeant Pharmaceuticals International SC TO-T/A SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (RULE 14d-100) Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 8) Salix Pharmaceuticals, Ltd. (Name of Subject Company (Issuer)) Sun Merger Sub, Inc. a wholly owned subsidiary of Valeant Pharmaceuticals International a wholly owned subs
March 25, 2015	EX-99.A.5.XII	Dear Valeant and Salix Colleagues: EX-99.A.5.XII 2 d895410dex99a5xii.htm EX-99.A.5.XII Exhibit (a)(5)(xii) Dear Valeant and Salix Colleagues: As Day 1 of our new combined company rapidly approaches, I would like to announce our executive leadership structure for Salix post-close. I would first like to thank all of you who are working tirelessly and professionally to bring our two companies together — planning our integration, raisi
March 20, 2015	SC 14D9/A	Salix Therapeuticals AMENDMENT NO. 5 TO SCHEDULE 14D-9 AMENDMENT NO. 5 TO SCHEDULE 14D-9 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Amendment No. 5) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 Salix Pharmaceuticals, Ltd. (Name of Subject Company) Salix Pharmaceuticals, Ltd. (Names of Persons Filing Statement) COMMON STOCK, PAR VALUE $0.001 PER SHARE (T
March 20, 2015	EX-99.A.26	1 EX-99.A.26 Exhibit (a)(26) Valeant Acquisition Question and Answer Document Salix Employees The following questions and answers are for use by leaders, managers and employees at Salix. These messages are to be used only as a guide ? creating a consistent reference point for communications related to the announcement and close of the acquisition by Valeant and integration activities. Purpose The pu
March 18, 2015	SC 14D9/A	Salix Therapeuticals SC 14D9/A SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Amendment No. 4) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 Salix Pharmaceuticals, Ltd. (Name of Subject Company) Salix Pharmaceuticals, Ltd. (Names of Persons Filing Statement) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Securit
March 18, 2015	SC TO-T/A	Valeant Pharmaceuticals International SC TO-T/A SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (RULE 14d-100) Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 7) Salix Pharmaceuticals, Ltd. (Name of Subject Company (Issuer)) Sun Merger Sub, Inc. a wholly owned subsidiary of Valeant Pharmaceuticals International a wholly owned subs
March 18, 2015	EX-99.A.23	31 WEST 52ND STREET, 22ND FLOOR, NEW YORK, NY 10019 PHONE: (212) 380-2650 FAX: (212) 380-2651 WWW.CENTERVIEWPARTNERS.COM NEW YORK — LONDON — SAN FRANCISCO — LOS ANGELES EX-99(a)(23) Annex D Centerview Partners LLC 31 West 52nd Street New York, NY 10019 March 15, 2015 The Board of Directors Salix Pharmaceuticals, Ltd.
March 18, 2015	EX-99.A.5.XI	Email to Salix Employees Exhibit (a)(5)(xi) Email to Salix Employees Dear Salix Employees: I wanted to reach out to all of you today and convey my apologies for the lack of communication over the past week, and for any delays regarding integration planning.
March 18, 2015	EX-99.A.24	E-1 EX-99(a)(24) Annex E March 15, 2015 The Board of Directors Salix Pharmaceuticals, Ltd.
March 17, 2015	EX-99.A.1.VII	Amendment and Supplement to the Offer to Purchase for Cash All Outstanding Shares of Common Stock Salix Pharmaceuticals, Ltd. $173.00 Per Share, Net in Cash Sun Merger Sub, Inc. a wholly-owned subsidiary of Valeant Pharmaceuticals International a who EX-99.A.1.VII 2 d892433dex99a1vii.htm EX.99.A.1.VII Exhibit (a)(1)(vii) Amendment and Supplement to the Offer to Purchase for Cash All Outstanding Shares of Common Stock of Salix Pharmaceuticals, Ltd. at $173.00 Per Share, Net in Cash by Sun Merger Sub, Inc. a wholly-owned subsidiary of Valeant Pharmaceuticals International a wholly-owned subsidiary of Valeant Pharmaceuticals International, Inc. T
March 17, 2015	SC TO-T/A	Valeant Pharmaceuticals International SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (RULE 14d-100) Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 6) Salix Pharmaceuticals, Ltd. (Name of Subject Company (Issuer)) Sun Merger Sub, Inc. a wholly owned subsidiary of Valeant Pharmaceuticals International a wholly owned subsidiary of
March 16, 2015	SC 14D9/A	Salix Therapeuticals SC 14D9/A SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Amendment No. 3) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 Salix Pharmaceuticals, Ltd. (Name of Subject Company) Salix Pharmaceuticals, Ltd. (Names of Persons Filing Statement) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Securit
March 16, 2015	EX-99.A.22	Employee Letter/Email EX-99.A.22 2 d890045dex99a22.htm EX-99.A.22 Exhibit (a)(22) Employee Letter/Email Dear Colleagues, I wanted to let you know that we have announced an amended agreement with Valeant that increases its offer to acquire Salix to $173.00 per share in cash, valuing Salix at approximately $15.8 billion. This increased offer represents a 9.5% premium over Valeant’s original offer price of $158.00 per sha
March 16, 2015	EX-99.A.5.X	VALEANT AND SALIX AGREE ON AMENDED TERMS TO MERGER AGREEMENT EX-99.A.5.X 2 d890282dex99a5x.htm EX-99.A.5.X Exhibit (a)(5)(x) International Headquarters 2150 St. Elzéar Blvd. West Laval, Quebec H7L 4A8 Phone: 514.744.6792 Fax: 514.744.6272 Contact Information: Valeant Investors: Salix Investors: Laurie W. Little Timothy J. Creech / Michael Freeman 949-461-6002 919-862-1000 [email protected] Valeant Media Contacts: Salix Media Contacts: Sard Verbinnen
March 16, 2015	SC TO-T/A	Valeant Pharmaceuticals International SC TO-T/A SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (RULE 14d-100) Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 5) Salix Pharmaceuticals, Ltd. (Name of Subject Company (Issuer)) Sun Merger Sub, Inc. a wholly owned subsidiary of Valeant Pharmaceuticals International a wholly owned subs
March 16, 2015	EX-99.1	VALEANT AND SALIX AGREE ON AMENDED TERMS TO MERGER AGREEMENT EX-99.1 Exhibit 99.1 Contact Information: Valeant Investors: Salix Investors: Laurie W. Little Timothy J. Creech / Michael Freeman 949-461-6002 919-862-1000 [email protected] Valeant Media Contacts: Salix Media Contacts: Sard Verbinnen & Co Teneo Strategy Ren?e Soto/ Meghan Gavigan/Jared Levy Stephen Cohen 212-687-8080 347-489-6602 VALEANT AND SALIX AGREE ON AMENDED TERMS TO MERGER AGREEME
March 16, 2015	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 16, 2015 SALIX PHARMACEUTICALS, LTD. (Exact name of registrant as specified in its charter) Delaware 000-23265 94-3267443 (State or other jurisdiction of incorporation) (Commiss
March 16, 2015	EX-2.1	AMENDMENT NO. 1 TO AGREEMENT AND PLAN OF MERGER EX-2.1 Exhibit 2.1 EXECUTION VERSION AMENDMENT NO. 1 TO AGREEMENT AND PLAN OF MERGER AMENDMENT NO. 1 (this ?Amendment?), dated as of March 16, 2015, to that certain Agreement and Plan of Merger, dated as of February 20, 2015 (the ?Agreement?), by and among Valeant Pharmaceuticals International, a Delaware corporation (?Parent?), Sun Merger Sub, Inc., a Delaware corporation and a wholly owned Subsi
March 13, 2015	EX-99.A.5.VIII	VALEANT ANNOUNCES PRICING OF PRIVATE OFFERING OF SENIOR NOTES VALEANT EXPECTS WAITING PERIOD UNDER HART-SCOTT-RODINO FOR SALIX ACQUISITION TO EXPIRE ON MARCH 16 EX-99.A.5.VIII 2 d890905dex99a5viii.htm EX-99.A.5.VIII Exhibit (a)(5)(viii) International Headquarters 2150 St. Elzéar Blvd. West Laval, Quebec H7L 4A8 Phone: 514.744.6792 Fax: 514.744.6272 Contact Information: Laurie W. Little Valeant Pharmaceuticals International, Inc. 949-461-6002 [email protected] Media: Renee E. Soto/Meghan Gavigan Sard Verbinnen & Co. 212-687-8080 [email protected]
March 13, 2015	EX-99.A.5.IX	VALEANT ANNOUNCES HSR CLEARANCE FOR SALIX ACQUISITION EX-99.A.5.IX 3 d890905dex99a5ix.htm EX-99.A.5.IX Exhibit (a)(5)(ix) International Headquarters 2150 St. Elzéar Blvd. West Laval, Quebec H7L 4A8 Phone: 514.744.6792 Fax: 514.744.6272 Contact Information: Laurie W. Little Valeant Pharmaceuticals International, Inc. 949-461-6002 [email protected] Media: Renee E. Soto/Meghan Gavigan Sard Verbinnen & Co. 212-687-8080 [email protected] / mgavig
March 13, 2015	SC TO-T/A	Valeant Pharmaceuticals International SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (RULE 14d-100) Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 4) Salix Pharmaceuticals, Ltd. (Name of Subject Company (Issuer)) Sun Merger Sub, Inc. a wholly owned subsidiary of Valeant Pharmaceuticals International a wholly owned subsidiary of
March 12, 2015	EX-99.A.5.VII	VALEANT COMMENTS ON ENDO OFFER TO ACQUIRE SALIX EX-99.A.5.VII Exhibit (a)(5)(vii) International Headquarters 2150 St. Elz?ar Blvd. West Laval, Quebec H7L 4A8 Phone: 514.744.6792 Fax: 514.744.6272 Contact Information: Valeant Investors: Laurie W. Little 949-461-6002 [email protected] Valeant Media Contacts: Sard Verbinnen & Co Ren?e Soto/ Meghan Gavigan/Jared Levy 212-687-8080 VALEANT COMMENTS ON ENDO OFFER TO ACQUIRE SALIX Laval, Quebec
March 12, 2015	EX-99.(A)(17)	Salix Pharmaceuticals, Ltd. Confirms Receipt of an Unsolicited Proposal from Endo International plc Exhibit (a)(19) Contact: G. Michael Freeman Stephen Cohen Associate Vice President, Investor Teneo Strategy Relations and Corporate Communications 919-862-1000 347-489-6602 For Immediate Release Salix Pharmaceuticals, Ltd. Confirms Receipt of an Unsolicited Proposal from Endo International plc Raleigh, NC March, 11, 2015 Salix Pharmaceuticals, Ltd. (Nasdaq: SLXP) (Salix or the Company) tod
March 12, 2015	SC TO-T/A	Valeant Pharmaceuticals International SC TO-T/A SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (RULE 14d-100) Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 3) Salix Pharmaceuticals, Ltd. (Name of Subject Company (Issuer)) Sun Merger Sub, Inc. a wholly owned subsidiary of Valeant Pharmaceuticals International a wholly owned subs
March 12, 2015	SC 14D9/A	Salix Therapeuticals SC 14D9/A SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Amendment No. 2) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 Salix Pharmaceuticals, Ltd. (Name of Subject Company) Salix Pharmaceuticals, Ltd. (Names of Persons Filing Statement) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Securit
March 9, 2015	EX-99.(A)(17)	Valeant Acquisition EX-99.(a)(17) Exhibit (a)(17) Valeant Acquisition Question and Answer Document Salix Employees The following questions and answers are for use by leaders, managers and employees at Salix. These messages are to be used only as a guide creating a consistent reference point for communications related to the announcement and close of the acquisition by Valeant and integration activities. Purpose The
March 9, 2015	EX-99.B.24	DEUTSCHE BANK AG NEW YORK BRANCH DEUTSCHE BANK AG CAYMAN ISLANDS BRANCH DEUTSCHE BANK SECURITIES INC. 60 Wall Street New York, NY 10005 EX-99.B.24 Exhibit (b)(24) EXECUTION VERSION DEUTSCHE BANK AG NEW YORK BRANCH DEUTSCHE BANK AG CAYMAN ISLANDS BRANCH DEUTSCHE BANK SECURITIES INC. 60 Wall Street New York, NY 10005 HSBC BANK USA, NATIONAL ASSOCIATION HSBC BANK CANADA THE HONGKONG AND SHANGHAI BANKING CORPORATION LIMITED HSBC SECURITIES (USA) INC. 452 Fifth Avenue, New York, NY 10018 THE BANK OF TOKYO-MITSUBISHI UFJ, LTD. 1251 Aven
March 9, 2015	SC 14D9/A	Salix Therapeuticals SC 14D9/A SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Amendment No. 1) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 Salix Pharmaceuticals, Ltd. (Name of Subject Company) Salix Pharmaceuticals, Ltd. (Names of Persons Filing Statement) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Securit
March 9, 2015	SC TO-T/A	Valeant Pharmaceuticals International SC TO-T/A SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (RULE 14d-100) Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 2) Salix Pharmaceuticals, Ltd. (Name of Subject Company (issuer)) Sun Merger Sub, Inc. a wholly owned subsidiary of Valeant Pharmaceuticals International a wholly owned subs
March 6, 2015	EX-99.(E)(26)	SALIX PHARMACEUTICALS, LTD. AMENDED AND RESTATED 2014 STOCK INCENTIVE PLAN TABLE OF CONTENTS ARTICLE 1 . INTRODUCTION 1 1.1. Purpose of the Plan. 1 1.2. Nature of Awards. 1 1.3. Effective Date and Term of Plan. 1 ARTICLE 2 . DEFINITIONS AND CONSTRUCT EX-99.(e)(26) Exhibit (e)(26) SALIX PHARMACEUTICALS, LTD. AMENDED AND RESTATED 2014 STOCK INCENTIVE PLAN TABLE OF CONTENTS ARTICLE 1 . INTRODUCTION 1 1.1. Purpose of the Plan. 1 1.2. Nature of Awards. 1 1.3. Effective Date and Term of Plan. 1 ARTICLE 2 . DEFINITIONS AND CONSTRUCTION 2 2.1. Definitions. 2 2.2. Construction. 5 ARTICLE 3 . ELIGIBILITY 6 3.1. In General. 6 ARTICLE 4 . ADMINISTRATION O
March 6, 2015	EX-99.(E)(29)	AMENDED AND RESTATED EMPLOYMENT AGREEMENT EX-99.(e)(29) Exhibit (e)(29) AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (?Agreement?) shall be effective as of the 1st day of February, 2015 (the ?Effective Date?) by and between Salix Pharmaceuticals, Inc., a California corporation with its principal place of business in Wake County, North Carolina (together with its subsidiaries, affiliates and succ
March 6, 2015	EX-99.(E)(28)	AMENDED AND RESTATED EMPLOYMENT AGREEMENT EX-99.(e)(28) Exhibit (e)(28) AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (?Agreement?) shall be effective as of the 5th day of January, 2015 (the ?Effective Date?) by and between Salix Pharmaceuticals, Inc., a California corporation with its principal place of business in Wake County, North Carolina (together with its subsidiaries, affiliates and succe
March 6, 2015	EX-99.B.23	AMENDMENT NO. 10 TO THIRD AMENDED AND RESTATED CREDIT AND GUARANTY AGREEMENT EX-99.B.23 Exhibit (b)(23) Execution Version AMENDMENT NO. 10 TO THIRD AMENDED AND RESTATED CREDIT AND GUARANTY AGREEMENT AMENDMENT NO. 10 TO THIRD AMENDED AND RESTATED CREDIT AND GUARANTY AGREEMENT, dated as of March 5, 2015 (this Amendment No. 10), by and among VALEANT PHARMACEUTICALS INTERNATIONAL, INC., a corporation continued under the laws of the Province of British Columbia (Borrower),
March 6, 2015	SC 14D9	Salix Therapeuticals SC 14D9 SC 14D9 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
March 6, 2015	SC TO-T/A	Valeant Pharmaceuticals International SC TO-T/A SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (RULE 14d-100) Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 1) Salix Pharmaceuticals, Ltd. (Name of Subject Company (Issuer)) Sun Merger Sub, Inc. a wholly owned subsidiary of Valeant Pharmaceuticals International a wholly owned subs
March 4, 2015	EX-99.A.1.V	Offer To Purchase For Cash All Outstanding Shares of Common Stock Salix Pharmaceuticals, Ltd. $158.00 Per Share, Net in Cash Pursuant to the Offer to Purchase dated March 4, 2015 Sun Merger Sub, Inc., a wholly owned subsidiary of Valeant Pharmaceutic EX-99.A.1.V Exhibit (a)(1)(v) Offer To Purchase For Cash All Outstanding Shares of Common Stock of Salix Pharmaceuticals, Ltd. at $158.00 Per Share, Net in Cash Pursuant to the Offer to Purchase dated March 4, 2015 by Sun Merger Sub, Inc., a wholly owned subsidiary of Valeant Pharmaceuticals International, a wholly owned subsidiary of Valeant Pharmaceuticals International, Inc. THE OFFER AND WITHD
March 4, 2015	EX-99.D.3	Salix Pharmaceuticals, Ltd. 8510 Colonnade Center Drive Raleigh, NC 27615 EX-99.D.3 Exhibit (d)(3) Salix Pharmaceuticals, Ltd. 8510 Colonnade Center Drive Raleigh, NC 27615 February 6, 2015 Valeant Pharmaceuticals International, Inc. 2150 St. Elzéar Blvd. West Laval, Quebec, Canada H7L 4A8 Attn: J. Michael Pearson Re: Confidentiality Agreement Ladies and Gentlemen: Reference is made to that certain letter agreement (the “Confidentiality Agreement”), dated January 20, 20
March 4, 2015	EX-99.A.1.I	Offer to Purchase for Cash All Outstanding Shares of Common Stock Salix Pharmaceuticals, Ltd. $158.00 Per Share, Net in Cash Sun Merger Sub, Inc., a wholly owned subsidiary of Valeant Pharmaceuticals International, a wholly owned subsidiary of Valean Table of Contents Exhibit (a)(1)(i) Offer to Purchase for Cash All Outstanding Shares of Common Stock of Salix Pharmaceuticals, Ltd.
March 4, 2015	EX-99.A.1.VI	This announcement is neither an offer to purchase nor a solicitation of an offer to sell Shares (as defined below). The Offer (as defined below) is made solely by the Offer to Purchase (as defined below) and the related Letter of Transmittal (as defi EX-99.A.1.VI Exhibit (a)(1)(vi) This announcement is neither an offer to purchase nor a solicitation of an offer to sell Shares (as defined below). The Offer (as defined below) is made solely by the Offer to Purchase (as defined below) and the related Letter of Transmittal (as defined below) and any amendments or supplements thereto. The Offer is not being made to (and no tenders will be accepted
March 4, 2015	SC TO-T	BHC / BauschHealth?Companies?Inc. SC TO-T - - SC TO-T SC TO-T UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (RULE 14d-100) Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 SALIX PHARMACEUTICALS, LTD. (Name of Subject Company (Issuer)) Sun Merger Sub, Inc. a wholly owned subsidiary of Valeant Pharmaceuticals International a wholly owned subsidiary of Valeant Ph
March 4, 2015	EX-99.A.1.II	LETTER OF TRANSMITTAL To Tender Shares of Common Stock Salix Pharmaceuticals, Ltd. $158.00 Per Share, Net in Cash Pursuant to the Offer to Purchase dated March 4, 2015 Sun Merger Sub, Inc., a wholly owned subsidiary of Valeant Pharmaceuticals Interna EX-99.A.1.II 3 d881645dex99a1ii.htm EX-99.A.1.II Exhibit (a)(1)(ii) LETTER OF TRANSMITTAL To Tender Shares of Common Stock of Salix Pharmaceuticals, Ltd. at $158.00 Per Share, Net in Cash Pursuant to the Offer to Purchase dated March 4, 2015 by Sun Merger Sub, Inc., a wholly owned subsidiary of Valeant Pharmaceuticals International, a wholly owned subsidiary of Valeant Pharmaceuticals Internationa
March 4, 2015	EX-99.D.2	Salix Pharmaceuticals, Ltd. 8510 Colonnade Center Drive Raleigh, NC 27615 EX-99.D.2 Exhibit (d)(2) Salix Pharmaceuticals, Ltd. 8510 Colonnade Center Drive Raleigh, NC 27615 January 20, 2015 Valeant Pharmaceuticals International, Inc. 2150 St. Elzéar Blvd. West Laval, Quebec, Canada H7L 4A8 Attn: J. Michael Pearson Ladies and Gentlemen: In connection with your consideration of a potential negotiated transaction between our two companies (the “Possible Transaction”), you
March 4, 2015	EX-99.A.1.IV	Offer To Purchase For Cash All Outstanding Shares of Common Stock Salix Pharmaceuticals, Ltd. $158.00 Per Share, Net in Cash Pursuant to the Offer to Purchase dated March 4, 2015 Sun Merger Sub, Inc., a wholly owned subsidiary of Valeant Pharmaceutic EX-99.A.1.IV Exhibit (a)(1)(iv) Offer To Purchase For Cash All Outstanding Shares of Common Stock of Salix Pharmaceuticals, Ltd. at $158.00 Per Share, Net in Cash Pursuant to the Offer to Purchase dated March 4, 2015 by Sun Merger Sub, Inc., a wholly owned subsidiary of Valeant Pharmaceuticals International, a wholly owned subsidiary of Valeant Pharmaceuticals International, Inc. THE OFFER AND WIT
March 4, 2015	EX-99.A.1.III	NOTICE OF GUARANTEED DELIVERY For Tender of All Outstanding Shares of Common Stock Salix Pharmaceuticals, Ltd. $158.00 Per Share, Net in Cash Pursuant to the Offer to Purchase dated March 4, 2015 Sun Merger Sub, Inc., a wholly owned subsidiary of Val EX-99.A.1.III Exhibit (a)(1)(iii) NOTICE OF GUARANTEED DELIVERY For Tender of All Outstanding Shares of Common Stock of Salix Pharmaceuticals, Ltd. at $158.00 Per Share, Net in Cash Pursuant to the Offer to Purchase dated March 4, 2015 by Sun Merger Sub, Inc., a wholly owned subsidiary of Valeant Pharmaceuticals International, a wholly owned subsidiary of Valeant Pharmaceuticals International, Inc
March 2, 2015	10-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (Amendment No. 1) 10-K/A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.
March 2, 2015	10-Q/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1) Form 10-Q/A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
March 2, 2015	10-Q/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1) 10-Q/A 1 d867094d10qa.htm FORM 10-Q/A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2014 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the tran
March 2, 2015	EX-99.1	Salix Pharmaceuticals Reports 4Q2014 and FY2014 Results EX-99.1 Exhibit 99.1 Contact: Timothy J. Creech G. Michael Freeman Senior Vice President, Finance and Associate Vice President, Investor Administrative Services and Acting Relations and Corporate Chief Financial Officer Communications 919-862-1000 919-862-1000 Salix Pharmaceuticals Reports 4Q2014 and FY2014 Results RALEIGH, NC, March 2, 2015 – Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP) (“Salix” or
March 2, 2015	EX-21.1	Salix Pharmaceuticals, Ltd. Subsidiaries Name Jurisdiction Salix Pharmaceuticals, Inc. California Oceana Therapeutics, Inc. Delaware Santarus, Inc. Delaware EX-21.1 Exhibit 21.1 Salix Pharmaceuticals, Ltd. Subsidiaries Name Jurisdiction Salix Pharmaceuticals, Inc. California Oceana Therapeutics, Inc. Delaware Santarus, Inc. Delaware
March 2, 2015	EX-21.1	Salix Pharmaceuticals, Ltd. Subsidiaries Exhibit 21.1 Salix Pharmaceuticals, Ltd. Subsidiaries Name Jurisdiction Salix Pharmaceuticals, Inc. California Oceana Therapeutics, Inc. Delaware Santarus, Inc. Delaware
March 2, 2015	10-Q/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1) Form 10-Q/A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
March 2, 2015	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 2, 2015 SALIX PHARMACEUTICALS, LTD. (Exact name of registrant as specified in its charter) Delaware 000-23265 94-3267443 (State or other jurisdiction of incorporation)
March 2, 2015	10-K	Salix Therapeuticals 10-K (Annual Report) 10-K 1 slxp-10k20141231.htm 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year ended December 31, 2014 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 00
February 27, 2015	8-K	Other Events 8-K 1 d879919d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 27, 2015 SALIX PHARMACEUTICALS, LTD. (Exact name of registrant as specified in its charter) Delaware 000-23265 94-3267443 (State or other jurisdictio
February 25, 2015	SC14D9C	SLXP / Salix Therapeuticals, Inc. SC14D9C - - SC14D9C SC14D9C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 SALIX PHARMACEUTICALS, LTD. (Name of Subject Company) SALIX PHARMACEUTICALS, LTD. (Names of Persons Filing Statement) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Securities) 795435106 (CUSI
February 25, 2015	EX-99.1	SALIX PROVIDES NOTICE OF ANTICIPATED MAKE-WHOLE FUNDAMENTAL CHANGE TO HOLDERS OF ITS 2.75% CONVERTIBLE SENIOR NOTES DUE 2015 EX-99.1 Exhibit 99.1 Contact Information: Salix Investors: Timothy J. Creech / Michael Freeman 919-862-1000 Salix Media Contacts: Teneo Strategy Stephen Cohen 347-489-6602 SALIX PROVIDES NOTICE OF ANTICIPATED MAKE-WHOLE FUNDAMENTAL CHANGE TO HOLDERS OF ITS 2.75% CONVERTIBLE SENIOR NOTES DUE 2015 Raleigh, NC — February 25, 2015 — Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP) (the “Company” or “Salix”)
February 25, 2015	EX-99.2	SALIX PROVIDES NOTICE OF ANTICIPATED MAKE-WHOLE FUNDAMENTAL CHANGE TO HOLDERS OF ITS 1.5% CONVERTIBLE SENIOR NOTES DUE 2019 EX-99.2 Exhibit 99.2 Contact Information: Salix Investors: Timothy J. Creech / Michael Freeman 919-862-1000 Salix Media Contacts: Teneo Strategy Stephen Cohen 347-489-6602 SALIX PROVIDES NOTICE OF ANTICIPATED MAKE-WHOLE FUNDAMENTAL CHANGE TO HOLDERS OF ITS 1.5% CONVERTIBLE SENIOR NOTES DUE 2019 Raleigh, NC — February 25, 2015 — Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP) (the “Company” or “Salix”)
February 24, 2015	SC TO-C	BHC / BauschHealth?Companies?Inc. SC TO-C - - SC TO-C SC TO-C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (RULE 14d–100) Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 SALIX PHARMACEUTICALS, LTD. (Name of Subject Company) Sun Merger Sub, Inc. a wholly owned subsidiary of Valeant Pharmaceuticals International a wholly owned subsidiary of Valeant Pharmaceuti
February 24, 2015	EX-99.1	Valeant Pharmaceuticals International, Inc. EX-99.1 Exhibit 99.1 Corrected Transcript 23-Feb-2015 Valeant Pharmaceuticals International, Inc. (VRX) Q4 2014 Earnings Call Total Pages: 24 1-877-FACTSET www.callstreet.com Copyright © 2001-2015 FactSet CallStreet, LLC Valeant Pharmaceuticals International, Inc. (VRX) Q4 2014 Earnings Call Corrected Transcript 23-Feb-2015 CORPORATE PARTICIPANTS Laurie W. Little J. Michael Pearson Senior Vice Pre
February 23, 2015	EX-99.1	Dear Colleagues, EX-99.1 2 d878966dex991.htm EX-99.1 Exhibit 99.1 Dear Colleagues, On behalf of our Board of Directors and Senior Staff, I am pleased to announce that we have entered into a definitive agreement to be acquired by Valeant. A copy of the press is attached to this email. The combination of Valeant and Salix will create a larger, stronger and more diversified leading specialty pharmaceutical company. T
February 23, 2015	EX-10.1	DEUTSCHE BANK AG NEW YORK BRANCH DEUTSCHE BANK AG CAYMAN ISLANDS BRANCH DEUTSCHE BANK SECURITIES INC. 60 Wall Street New York, NY 10005 EX-10.1 EXHIBIT 10.1 EXECUTION VERSION DEUTSCHE BANK AG NEW YORK BRANCH DEUTSCHE BANK AG CAYMAN ISLANDS BRANCH DEUTSCHE BANK SECURITIES INC. 60 Wall Street New York, NY 10005 HSBC BANK USA, NATIONAL ASSOCIATION HSBC BANK CANADA THE HONGKONG AND SHANGHAI BANKING CORPORATION LIMITED HSBC SECURITIES (USA) INC. 452 Fifth Avenue, New York, NY 10018 THE BANK OF TOKYO-MITSUBISHI UFJ, LTD. 1251 Avenue of
February 23, 2015	EX-10.1	DEUTSCHE BANK AG NEW YORK BRANCH DEUTSCHE BANK AG CAYMAN ISLANDS BRANCH DEUTSCHE BANK SECURITIES INC. 60 Wall Street New York, NY 10005 EX-10.1 EXHIBIT 10.1 EXECUTION VERSION DEUTSCHE BANK AG NEW YORK BRANCH DEUTSCHE BANK AG CAYMAN ISLANDS BRANCH DEUTSCHE BANK SECURITIES INC. 60 Wall Street New York, NY 10005 HSBC BANK USA, NATIONAL ASSOCIATION HSBC BANK CANADA THE HONGKONG AND SHANGHAI BANKING CORPORATION LIMITED HSBC SECURITIES (USA) INC. 452 Fifth Avenue, New York, NY 10018 THE BANK OF TOKYO-MITSUBISHI UFJ, LTD. 1251 Avenue of
February 23, 2015	EX-99.1	VALEANT PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2014 FINANCIAL RESULTS PROVIDING FIRST QUARTER 2015 CASH EPS GUIDANCE DENDREON ACQUISITION EXPECTED TO CLOSE FEBRUARY 23, 2015 VALEANT TO ACQUIRE SALIX PHARMACEUTICALS FOR $158.00 PER SHARE EX-99.1 Exhibit 99.1 International Headquarters 2150 St. Elzéar Blvd. West Laval, Quebec H7L 4A8 Phone: 514.744.6792 Fax: 514.744.6272 Contact Information: Laurie W. Little 949-461-6002 [email protected] VALEANT PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2014 FINANCIAL RESULTS PROVIDING FIRST QUARTER 2015 CASH EPS GUIDANCE DENDREON ACQUISITION EXPECTED TO CLOSE FEBRUARY 23, 2015
February 23, 2015	EX-99.2	Dear Colleagues, Exhibit 99.2 Dear Colleagues, Earlier today, we announced that Valeant has agreed to acquire Salix Pharmaceuticals, a mid-sized specialty pharmaceutical company with a unique focus on gastrointestinal (GI) treatments. This acquisition will create a new platform for Valeant in the GI market, a therapeutic area that has strong growth prospects and a concentrated specialist prescriber population. The
February 23, 2015	EX-2.1	AGREEMENT AND PLAN OF MERGER by and among VALEANT PHARMACEUTICALS INTERNATIONAL, SUN MERGER SUB, INC., VALEANT PHARMACEUTICALS INTERNATIONAL, INC. SALIX PHARMACEUTICALS, LTD. Dated as of February 20, 2015 TABLE OF CONTENTS Page ARTICLE I THE OFFER AN EX-2.1 Exhibit 2.1 AGREEMENT AND PLAN OF MERGER by and among VALEANT PHARMACEUTICALS INTERNATIONAL, SUN MERGER SUB, INC., VALEANT PHARMACEUTICALS INTERNATIONAL, INC. and SALIX PHARMACEUTICALS, LTD. Dated as of February 20, 2015 TABLE OF CONTENTS Page ARTICLE I THE OFFER AND THE MERGER 2 1.1 The Offer. 2 1.2 Company Actions. 4 1.3 The Merger. 5 1.4 Closing and Effective Time of the Merger. 6 ARTICL
February 23, 2015	EX-99.1	Contact Information: Valeant Investors: Salix Investors: Laurie W. Little Timothy J. Creech / Michael Freeman 949-461-6002 919-862-1000 [email protected] Valeant Media Contacts: Salix Media Contacts: Sard Verbinnen & Co Teneo Strategy Renée S EX-99.1 Exhibit 99.1 Contact Information: Valeant Investors: Salix Investors: Laurie W. Little Timothy J. Creech / Michael Freeman 949-461-6002 919-862-1000 [email protected] Valeant Media Contacts: Salix Media Contacts: Sard Verbinnen & Co Teneo Strategy Renée Soto/ Meghan Gavigan/Jared Levy Stephen Cohen 212-687-8080 347-489-6602 VALEANT TO ACQUIRE SALIX PHARMACEUTICALS FOR $158.00 PER S
February 23, 2015	SC14D9C	SLXP / Salix Therapeuticals, Inc. SC14D9C - - SC14D9C SC14D9C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 SALIX PHARMACEUTICALS, LTD. (Name of Subject Company) SALIX PHARMACEUTICALS, LTD. (Names of Persons Filing Statement) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Securities) 795435106 (CUSI
February 23, 2015	EX-2.1	AGREEMENT AND PLAN OF MERGER by and among VALEANT PHARMACEUTICALS INTERNATIONAL, SUN MERGER SUB, INC., VALEANT PHARMACEUTICALS INTERNATIONAL, INC. SALIX PHARMACEUTICALS, LTD. Dated as of February 20, 2015 TABLE OF CONTENTS Page ARTICLE I THE OFFER AN EX-2.1 Exhibit 2.1 EXECUTION COPY AGREEMENT AND PLAN OF MERGER by and among VALEANT PHARMACEUTICALS INTERNATIONAL, SUN MERGER SUB, INC., VALEANT PHARMACEUTICALS INTERNATIONAL, INC. and SALIX PHARMACEUTICALS, LTD. Dated as of February 20, 2015 TABLE OF CONTENTS Page ARTICLE I THE OFFER AND THE MERGER 2 1.1 The Offer. 2 1.2 Company Actions. 4 1.3 The Merger. 5 1.4 Closing and Effective Time of the M
February 23, 2015	EX-99.3	Email to Salix Employees EX-99.3 Exhibit 99.3 Email to Salix Employees Dear Salix Employees, As Valeant’s Chairman and CEO, I wanted to personally let you know how excited we are about today’s news that our two companies will be coming together. The agreement we announced today to combine Salix’s market-leading gastrointestinal (GI) business with Valeant will create an even stronger, growth- oriented specialty pharmaceuti
February 23, 2015	EX-99.1	VALEANT TO ACQUIRE SALIX PHARMACEUTICALS FOR $158.00 PER SHARE IN CASH EX-99.1 Exhibit 99.1 VALEANT TO ACQUIRE SALIX PHARMACEUTICALS FOR $158.00 PER SHARE IN CASH • Salix is the Leader in the Growing U.S. Gastrointestinal Market • Transaction Creates a New Specialty Platform for Growth • Key Promoted Products Showing Strong, Double Digit Volume Growth, Far Exceeding the Market • Expected Near-Term Approval for IBS-D Indication of Xifaxan Additional Catalyst for Futur
February 23, 2015	SC TO-C	BHC / BauschHealth?Companies?Inc. SC TO-C - - SC TO-C SC TO-C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (RULE 14d–100) Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 SALIX PHARMACEUTICALS, LTD. (Name of Subject Company) Sun Merger Sub, Inc. a wholly owned subsidiary of Valeant Pharmaceuticals International a wholly owned subsidiary of Valeant Pharmaceuti
February 23, 2015	SC TO-C	BHC / BauschHealth?Companies?Inc. SC TO-C - - SC TO-C SC TO-C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (RULE 14d–100) Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 SALIX PHARMACEUTICALS, LTD. (Name of Subject Company) Sun Merger Sub, Inc. a wholly owned subsidiary of Valeant Pharmaceuticals International a wholly owned subsidiary of Valeant Pharmaceuti
February 23, 2015	SC TO-C	BHC / BauschHealth?Companies?Inc. SC TO-C - - FORM 8-K FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of the earliest event reported): February 23, 2015 (February 20, 2015) Valeant Pharmaceuticals International, Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-1495
February 23, 2015	EX-99.1	International, Inc. EX-99.1 Valeant Pharmaceuticals International, Inc. February 23, 2015 Exhibit 99.1 Fourth Quarter and Full Year 2014 Financial Results and The Acquisition of Salix Pharmaceuticals 1 Forward-looking Statements Note 1: The guidance in this presentation is only effective as of the date given, February 23, 2015, and will not be updated or affirmed unless and until the Company publicly announces update
February 23, 2015	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 20, 2015 SALIX PHARMACEUTICALS, LTD. (Exact name of registrant as specified in its charter) Delaware 000-23265 94-3267443 (State or other jurisdiction of incorporati
February 23, 2015	8-K	Other Events Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 19, 2015 SALIX PHARMACEUTICALS, LTD. (Exact name of registrant as specified in its charter) Delaware 000-23265 94-3267443 (State or other jurisdiction of incorporati
February 17, 2015	8-K	Financial Statements and Exhibits, Other Events Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 16, 2015 SALIX PHARMACEUTICALS, LTD. (Exact name of registrant as specified in its charter) Delaware 000-23265 94-3267443 (State or other jurisdiction of incorporati
February 17, 2015	SC 13G	SLXP / Salix Therapeuticals, Inc. / PAULSON & CO. INC. Passive Investment SC 13G 1 formsc13g-salix.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Salix Pharmaceuticals, Ltd. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 795435106 (CUSIP Number) December 31, 2014 (Date of Event which Requires Filing of this Statement) Check the
February 17, 2015	EX-99.1	SALIX PHARMACEUTICALS ANNOUNCES 4Q AND FY2014 FINANCIAL RESULTS CONFERENCE CALL AND WEBCAST EX-99.1 Exhibit 99.1 SALIX PHARMACEUTICALS ANNOUNCES 4Q AND FY2014 FINANCIAL RESULTS CONFERENCE CALL AND WEBCAST Monday, February 16, 2015, 7:00 am EST RALEIGH, N.C.—(BUSINESS WIRE)—Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the Company will report fourth quarter and full year 2014 financial results following the close of the U.S. financial markets on Monday, March 2, 2015. The
February 13, 2015	EX-10.1	LICENSE AGREEMENT BY AND AMONG COWEN HEALTHCARE ROYALTY PARTNERS, L.P. SHORE THERAPEUTICS, INC. SANTARUS, INC. DECEMBER 21, 2011 TABLE OF CONTENTS Page ARTICLE 1. Definitions 1 1.1 “Adverse Event” 1 1.2 “Additional Product” 1 1.3 “Affiliate” 2 1.4 “A EX-10.1 Exhibit 10.1 CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. Execution Copy LICENSE AGREEMENT BY AND AMONG COWEN HEALTHCARE ROYALTY PARTNERS, L.P. AND SHORE THERAPEUTICS, INC. AND SANTARUS, INC. DATED DECEMBER 21, 2011
February 13, 2015	EX-10.1	LICENSE AGREEMENT BY AND AMONG COWEN HEALTHCARE ROYALTY PARTNERS, L.P. SHORE THERAPEUTICS, INC. SANTARUS, INC. DECEMBER 21, 2011 TABLE OF CONTENTS Page ARTICLE 1. Definitions 1 1.1 “Adverse Event” 1 1.2 “Additional Product” 1 1.3 “Affiliate” 2 1.4 “A EX-10.1 Exhibit 10.1 CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. Execution Copy LICENSE AGREEMENT BY AND AMONG COWEN HEALTHCARE ROYALTY PARTNERS, L.P. AND SHORE THERAPEUTICS, INC. AND SANTARUS, INC. DATED DECEMBER 21, 2011
February 13, 2015	8-K	Financial Statements and Exhibits, Other Events 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 21, 2011 SALIX PHARMACEUTICALS, LTD. (Exact name of registrant as specified in its charter) Delaware 000-23265 94-3267443 (State or other jurisdiction of incorporation) (
February 12, 2015	SC 13G/A	SLXP / Salix Therapeuticals, Inc. / TEACHERS ADVISORS INC Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO §240.13D-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO §240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.1 )* Salix Pharmaceuticals, Ltd. (Name of Issuer) Common Stock (Title of Class of Securities) 794535106 (CUSIP Number) D
February 12, 2015	LETTER	LETTER February 12, 2015 Via E-mail Mr. Tom D’Alonzo Acting Chief Executive Officer Salix Pharmaceuticals, Ltd. 8510 Colonnade Center Drive Raleigh, NC 27615 Re: Salix Pharmaceuticals, Ltd. Item 4.02 Form 8-K Filed January 28, 2015 File No. 000-23265 Dear Mr. D’Alonzo: We have completed our review of your filing. We remind you that our comments or changes to disclosure in response to our comments do not
February 12, 2015	SC 13G/A	SLXP / Salix Therapeuticals, Inc. / TIAA CREF INVESTMENT MANAGEMENT LLC Passive Investment SC 13G/A 1 c8020313ga.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO §240.13D-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO §240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.1 )* Salix Pharmaceuticals, Ltd. (Name of Issuer) Common Stock (Title of Class of Securities)
February 12, 2015	SC 13G/A	SLXP / Salix Therapeuticals, Inc. / Wellington Management Group LLP - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 16 )* Salix Pharmaceuticals, Ltd. (Name of Issuer) Common Stock (Title of Class of Securities) 795435106 (CUSIP Number) December 31, 2014 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whic
February 12, 2015	SC 13G/A	SLXP / Salix Therapeuticals, Inc. / Visium Asset Management, LP - SC 13G/A Passive Investment SC 13G/A 1 d871468dsc13ga.htm SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Salix Pharmaceuticals, Ltd. (Name of Issuer) Common Stock, $0.001 per share (Title of Class of Securities) 795435106 (CUSIP Number) December 31, 2014 (Date of Event Which Requires Filing of this Statement) Check the appropriate b
February 10, 2015	SC 13G/A	SLXP / Salix Therapeuticals, Inc. / VANGUARD GROUP INC Passive Investment salixpharmaceuticalsltd.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 3 )* Name of issuer: Salix Pharmaceuticals Ltd Title of Class of Securities: Common Stock CUSIP Number: 795435106 Date of Event Which Requires Filing of this Statement: December 31, 2014 Check the ap
February 6, 2015	CORRESP	SLXP / Salix Therapeuticals, Inc. CORRESP - - Correspondence February 6, 2015 VIA EDGAR CORRESPONDENCE Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.
February 5, 2015	EX-99.1	Salix Announces the Promotion of William P. Forbes, PharmD to President, Medical, R&D and Chief Development Officer EX-99.1 Exhibit 99.1 Contact: Timothy J. Creech G. Michael Freeman Senior Vice President, Finance & Associate Vice President, Investor Administrative Services and Acting Chief Relations and Corporate Financial Officer Communications 919-862-1000 919-862-1000 Salix Announces the Promotion of William P. Forbes, PharmD to President, Medical, R&D and Chief Development Officer RALEIGH, NC, February 2,
February 5, 2015	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Other Events Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 30, 2015 SALIX PHARMACEUTICALS, LTD. (Exact name of registrant as specified in its charter) Delaware 000-23265 94-3267443 (State or other jurisdiction of incorporatio
February 3, 2015	LETTER	LETTER February 2, 2015 Via E-mail Mr. Tom D’Alonzo Acting Chief Executive Officer Salix Pharmaceuticals, Ltd. 8510 Colonnade Center Drive Raleigh, NC 27615 Re: Salix Pharmaceuticals, Ltd. Item 4.02 Form 8-K Filed January 28, 2015 File No. 000-23265 Dear Mr. D’Alonzo: We have reviewed your filing and have the following comment. In our comment, we ask you to provide us with information so we may better un
February 2, 2015	8-K	Other Events Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 2, 2015 SALIX PHARMACEUTICALS, LTD. (Exact name of registrant as specified in its charter) Delaware 000-23265 94-3267443 (State or other jurisdiction of incorporatio
January 30, 2015	8-K/A	Regulation FD Disclosure, Financial Statements and Exhibits Form 8-K Amendment No. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 16, 2014 SALIX PHARMACEUTICALS, LTD. (Exact name of registrant as specified in its charter) Delaware 000-23265 94-3267443 (State
January 28, 2015	EX-99.1	Salix Provides Update on Audit Committee Review Audit Committee Determines to Restate Financial Statements for FY2013 and First Three Quarters of 2014 *Aggregate impact of errors on net product revenue and net income over all previously reported peri EX-99.1 2 d859676dex991.htm EX-99.1 Exhibit 99.1 Contact: Timothy J. Creech Senior Vice President, Finance & Administrative Services and Acting Chief Financial Officer 919-862-1000 G. Michael Freeman Associate Vice President, Investor Relations and Corporate Communications 919-862-1000 Salix Provides Update on Audit Committee Review Audit Committee Determines to Restate Financial Statements for FY
January 28, 2015	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 22, 2015 SALIX PHARMACEUTICALS, LTD. (Exact name of registrant as specified in its charter) Delaware 000-23265 94-3267443 (State or other jurisdiction of incorporation) (C
January 12, 2015	8-K	Entry into a Material Definitive Agreement Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 9, 2015 SALIX PHARMACEUTICALS, LTD. (Exact name of registrant as specified in its charter) Delaware 000-23265 94-3267443 (State or other jurisdiction of incorporation
January 9, 2015	EX-99.1	PHARMING AND SALIX ANNOUNCE FIRST PATIENT TREATED IN CLINICAL STUDY OF RUCONEST® FOR PROPHYLAXIS OF HEREDITARY ANGIOEDEMA EX-99.1 Exhibit 99.1 PHARMING AND SALIX ANNOUNCE FIRST PATIENT TREATED IN CLINICAL STUDY OF RUCONEST® FOR PROPHYLAXIS OF HEREDITARY ANGIOEDEMA LEIDEN, THE NETHERLANDS, RALEIGH, NC, 08 January 2015 — Pharming Group NV (EURONEXT: PHARM) and Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the first patient was treated in their Phase 2 clinical study of Ruconest®, (C1 Esterase Inhibitor
January 9, 2015	8-K	Financial Statements and Exhibits, Other Events 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 8, 2015 SALIX PHARMACEUTICALS, LTD. (Exact name of registrant as specified in its charter) Delaware 000-23265 94-3267443 (State or other jurisdiction of incorporation) (Co
January 5, 2015	EX-99.1	Carolyn Logan to Retire as Chief Executive Officer of Salix Pharmaceuticals EX-99.1 Exhibit 99.1 Contact: Timothy J. Creech Senior Vice President, Finance & Administrative Services and Acting Chief Financial Officer 919-862-1000 G. Michael Freeman Associate Vice President, Investor Relations and Corporate Communications 919-862-1000 Steve Cohen Teneo Strategy 347-489-6602 Carolyn Logan to Retire as Chief Executive Officer of Salix Pharmaceuticals RALEIGH, NC, January 5, 2
January 5, 2015	EX-10.1	8510 Colonnade Center Drive, Raleigh, NC 27615 www.salix.com T• 919.862.1000 F• 919.862.1095 EX-10.1 2 d845893dex101.htm EX-10.1 Exhibit 10.1 December 30, 2014 Ms. Carolyn J. Logan Salix Pharmaceuticals, Ltd. 8510 Colonnade Center Drive Raleigh, NC 27615 Dear Carolyn: You have informed Salix Pharmaceuticals, Inc. (“Salix” and, collectively with its subsidiaries and affiliates and their respective successors and assigns, the “Company”) of your decision to retire from the Company effective
January 5, 2015	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Other Events 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 30, 2014 SALIX PHARMACEUTICALS, LTD. (Exact name of registrant as specified in its charter) Delaware 000-23265 94-3267443 (State or other jurisdiction of incorporation) (
January 5, 2015	EX-10.1	8510 Colonnade Center Drive, Raleigh, NC 27615 www.salix.com T• 919.862.1000 F• 919.862.1095 EX-10.1 2 d845893dex101.htm EX-10.1 Exhibit 10.1 December 30, 2014 Ms. Carolyn J. Logan Salix Pharmaceuticals, Ltd. 8510 Colonnade Center Drive Raleigh, NC 27615 Dear Carolyn: You have informed Salix Pharmaceuticals, Inc. (“Salix” and, collectively with its subsidiaries and affiliates and their respective successors and assigns, the “Company”) of your decision to retire from the Company effective
December 30, 2014	LETTER	LETTER December 30, 2014 Via E-mail Carolyn J. Logan President and Chief Executive Officer Salix Pharmaceuticals, Ltd. 8510 Colonnade Center Drive Raleigh, NC 27615 Re: Salix Pharmaceuticals, Ltd. Form 10-K for the Fiscal Year Ended December 31, 2013 Filed February 28, 2014 File No. 000-23265 Dear Ms. Logan: We have completed our review of your filings. We remind you that our comments or changes to discl
December 16, 2014	8-K	Regulation FD Disclosure, Financial Statements and Exhibits Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 16, 2014 SALIX PHARMACEUTICALS, LTD. (Exact name of registrant as specified in its charter) Delaware 000-23265 94-3267443 (State or other jurisdiction of incorporati
December 16, 2014	EX-99.1	Salix Pharmaceuticals Provides Updates on Wholesaler Inventory Reductions and the XIFAXAN® 550 for IBS-D Approval Timeline, and Provides Preliminary Guidance for 2015 and 2016 Expects to Achieve Wholesale Inventory Targets by Year End 2015 Announces EX-99.1 Exhibit 99.1 Contact: Timothy J. Creech G. Michael Freeman Senior Vice President, Finance & Administrative Services and Acting Chief Financial Officer Associate Vice President, Investor Relations and Corporate Communications 919-862-1000 919-862-1000 Salix Pharmaceuticals Provides Updates on Wholesaler Inventory Reductions and the XIFAXAN® 550 for IBS-D Approval Timeline, and Provides Prel
December 10, 2014	SC 13G/A	SLXP / Salix Therapeuticals, Inc. / Wellington Management Group LLP - DISCLOSURE DOCUMENT Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 15)* Salix Pharmaceuticals, Ltd. (Name of Issuer) Common Stock (Title of Class of Securities) 795435106 (CUSIP Number) November 28, 2014 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which
December 8, 2014	CORRESP	SLXP / Salix Therapeuticals, Inc. CORRESP - - CORRESP [Salix Pharmaceuticals, Ltd. Letterhead] December 8, 2014 VIA EDGAR CORRESPONDENCE Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Joel Parker, Accounting Branch Chief, and Jim B. Rosenberg, Senior Assistant Chief Accountant Re: Salix Pharmaceuticals, Ltd. Form 10-K for the Fiscal Year Ended December 31, 2013 Filed Feb
November 25, 2014	8-K	Financial Statements and Exhibits, Other Events Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 24, 2014 SALIX PHARMACEUTICALS, LTD. (Exact name of registrant as specified in its charter) Delaware 000-23265 94-3267443 (State or other jurisdiction of incorporati
November 25, 2014	EX-99.1	Salix Pharmaceuticals Announces Plan to Augment Board of Directors EX-99.1 Exhibit 99.1 Contact: Timothy J. Creech G. Michael Freeman Senior Vice President, Associate Vice President, Investor Relations Finance and Administrative and Corporate Communications Services and Acting Chief Financial Officer Salix Pharmaceuticals Announces Plan to Augment Board of Directors RALEIGH, NC, November 24, 2014 – Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP) (“Salix” or the “Compa
November 21, 2014	LETTER	LETTER November 21, 2014 Via E-mail Carolyn J. Logan President and Chief Executive Officer Salix Pharmaceuticals, Ltd. 8510 Colonnade Center Drive Raleigh, NC 27615 Re: Salix Pharmaceuticals, Ltd. Form 10-K for the Fiscal Year Ended December 31, 2013 Filed February 28, 2014 Form 10-Q for the Period Ended June 30, 2014 Filed August 8, 2014 File No. 000-23265 Dear Ms. Logan: We have reviewed your November
November 17, 2014	SC 13G/A	SLXP / Salix Therapeuticals, Inc. / Visium Asset Management, LP - AMENDMENT NO.1 TO SCHEDULE 13G Passive Investment SC 13G/A 1 d822744dsc13ga.htm AMENDMENT NO.1 TO SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Salix Pharmaceuticals, Ltd. (Name of Issuer) Common Stock, $0.001 per share (Title of Class of Securities) 795435106 (CUSIP Number) November 7, 2014 (Date of Event Which Requires Filing of this Statement) Ch
November 7, 2014	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 5, 2014 SALIX PHARMACEUTICALS, LTD. (Exact name of registrant as specified in its charter) Delaware 000-23265 94-3267443 (State or other jurisdiction of incorporation) (C
November 7, 2014	EX-10.1	Salix Pharmaceuticals, Inc. 8510 Colonnade Center Drive Raleigh, NC 27615 EX-10.1 2 d815924dex101.htm EX-10.1 Exhibit 10.1 Salix Pharmaceuticals, Inc. 8510 Colonnade Center Drive Raleigh, NC 27615 November 5, 2014 Mr. Adam C. Derbyshire [Address on file with Registrant] Dear Adam: This letter agreement (this “Agreement”) sets forth our mutual understanding and agreement regarding your resignation of your employment with Salix Pharmaceuticals, Inc. (“Salix” and, collecti
November 7, 2014	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q 10-Q 1 d796453d10q.htm 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2014 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Co
November 7, 2014	EX-10.1	Salix Pharmaceuticals, Inc. 8510 Colonnade Center Drive Raleigh, NC 27615 EX-10.1 2 d815924dex101.htm EX-10.1 Exhibit 10.1 Salix Pharmaceuticals, Inc. 8510 Colonnade Center Drive Raleigh, NC 27615 November 5, 2014 Mr. Adam C. Derbyshire [Address on file with Registrant] Dear Adam: This letter agreement (this “Agreement”) sets forth our mutual understanding and agreement regarding your resignation of your employment with Salix Pharmaceuticals, Inc. (“Salix” and, collecti
November 7, 2014	EX-99.1	Salix Pharmaceuticals Appoints Acting Chief Financial Officer EX-99.1 3 d815924dex991.htm EX-99.1 Exhibit 99.1 Contact: Timothy J. Creech Senior Vice President, Finance and Administrative Services and Acting Chief Financial Officer 919-862-1000 G. Michael Freeman Associate Vice President, Investor Relations and Corporate Communications 919-862-1000 Salix Pharmaceuticals Appoints Acting Chief Financial Officer RALEIGH, NC, November 6, 2014 – Salix Pharmaceuti
November 6, 2014	EX-99.1	Salix Pharmaceuticals Reports 3Q2014 Results 3Q14 Total Net Product Revenue Increases 49% Year-over-Year to $355 million 3Q14 EBITDA Increases 63% Year-over-Year to $161 million 3Q14 XIFAXAN® 550 Prescriptions Increase 23% Year-over-Year and 4% vs. 2 EX-99.1 Exhibit 99.1 Contact: Timothy J. Creech G. Michael Freeman Senior Vice President, Associate Vice President, Investor Relations Finance and Administrative and Corporate Communications Services and Acting 919-862-1000 Chief Financial Officer 919-862-1000 Salix Pharmaceuticals Reports 3Q2014 Results 3Q14 Total Net Product Revenue Increases 49% Year-over-Year to $355 million 3Q14 EBITDA Increa
November 6, 2014	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 6, 2014 SALIX PHARMACEUTICALS, LTD. (Exact name of registrant as specified in its charter) Delaware 000-23265 94-3267443 (State or other jurisdiction of incorporation) (C
November 4, 2014	EX-99.1	Salix and Pharming Announce the Launch of RUCONEST® in the U.S. for the Treatment of Acute Angioedema Attacks in Patients with Hereditary Angioedema (HAE) RUCONEST® (C1 ESTERASE INHIBITOR [RECOMBINANT]) 50 IU/kg IS THE FIRST AND ONLY RECOMBINANT TREA EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Contact: Adam C. Derbyshire G. Michael Freeman Executive Vice President and Chief Financial Officer Associate Vice President, Investor Relations and Corporate Communications 919-862-1000 919-862-1000 Salix and Pharming Announce the Launch of RUCONEST® in the U.S. for the Treatment of Acute Angioedema Attacks in Patients with Hereditary Angioedema (HAE) RU
November 4, 2014	EX-10.2	Dated 11 September 2014 Dr. Falk Pharma GmbH - and - Salix Pharmaceuticals, Inc. FIRST AMENDMENT TO LICENSE AGREEMENT EX-10.2 Exhibit 10.2 EXECUTION VERSION CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. Dated 11 September 2014 Dr. Falk Pharma GmbH - and - Salix Pharmaceuticals, Inc. FIRST AMENDMENT TO LICENSE AGREEMENT (Budesonide) THIS FIR
November 4, 2014	CORRESP	SLXP / Salix Therapeuticals, Inc. CORRESP - - Correspondence [Salix Letterhead] November 4, 2014 VIA EDGAR CORRESPONDENCE Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.
November 4, 2014	EX-10.1	Dated 11 September 2014 Dr. Falk Pharma GmbH - and - Salix Pharmaceuticals, Inc. SECOND AMENDMENT TO LICENSE AGREEMENT EX-10.1 Exhibit 10.1 EXECUTION VERSION CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. Dated 11 September 2014 Dr. Falk Pharma GmbH - and - Salix Pharmaceuticals, Inc. SECOND AMENDMENT TO LICENSE AGREEMENT (Mesalamine) THIS SE
November 4, 2014	EX-10.2	Dated 11 September 2014 Dr. Falk Pharma GmbH - and - Salix Pharmaceuticals, Inc. FIRST AMENDMENT TO LICENSE AGREEMENT EX-10.2 Exhibit 10.2 EXECUTION VERSION CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. Dated 11 September 2014 Dr. Falk Pharma GmbH - and - Salix Pharmaceuticals, Inc. FIRST AMENDMENT TO LICENSE AGREEMENT (Budesonide) THIS FIR
November 4, 2014	EX-10.1	Dated 11 September 2014 Dr. Falk Pharma GmbH - and - Salix Pharmaceuticals, Inc. SECOND AMENDMENT TO LICENSE AGREEMENT EX-10.1 Exhibit 10.1 EXECUTION VERSION CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. Dated 11 September 2014 Dr. Falk Pharma GmbH - and - Salix Pharmaceuticals, Inc. SECOND AMENDMENT TO LICENSE AGREEMENT (Mesalamine) THIS SE
November 4, 2014	8-K	Financial Statements and Exhibits, Other Events 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 11, 2014 SALIX PHARMACEUTICALS, LTD. (Exact name of registrant as specified in its charter) Delaware 000-23265 94-3267443 (State or other jurisdiction of incorporation)
October 24, 2014	LETTER	LETTER October 24, 2014 Via E-mail Carolyn J. Logan President and Chief Executive Officer Salix Pharmaceuticals, Ltd. 8510 Colonnade Center Drive Raleigh, NC 27615 Re: Salix Pharmaceuticals, Ltd. Form 10-K for the Fiscal Year Ended December 31, 2013 Filed February 28, 2014 Form 10-Q for the Quarterly Period Ended June 30, 2014 Filed August 8, 2014 File No. 000-23265 Dear Ms. Logan: We have limited our re
October 23, 2014	EX-99.1	Salix’s TARGET 3 Study Examines the Safety and Efficacy of Repeat Treatment with Rifaximin 550 mg for Irritable Bowel Syndrome with Diarrhea Study Results Presented at the American College of Gastroenterology (ACG) Scientific Meeting in Philadelphia EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Contact: Adam C. Derbyshire G. Michael Freeman Executive Vice President Associate Vice President, Investor Relations and Chief Financial Officer and Corporate Communications 919-862-1000 919-862-1000 Salix’s TARGET 3 Study Examines the Safety and Efficacy of Repeat Treatment with Rifaximin 550 mg for Irritable Bowel Syndrome with Diarrhea Study Results Pr
October 23, 2014	EX-99.2	SALIX PHARMACEUTICALS ANNOUNCES 3Q2014 FINANCIAL RESULTS CONFERENCE CALL AND WEBCAST EX-99.2 Exhibit 99.2 FOR IMMEDIATE RELEASE Contact: Adam C. Derbyshire G. Michael Freeman Executive Vice President Associate Vice President, Investor Relations and Chief Financial Officer and Corporate Communications 919-862-1000 919-862-1000 SALIX PHARMACEUTICALS ANNOUNCES 3Q2014 FINANCIAL RESULTS CONFERENCE CALL AND WEBCAST RALEIGH, NC, October 23, 2014 - Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP
October 23, 2014	8-K	Financial Statements and Exhibits, Other Events Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 21, 2014 SALIX PHARMACEUTICALS, LTD. (Exact name of registrant as specified in its charter) Delaware 000-23265 94-3267443 (State or other jurisdiction of incorporatio
October 17, 2014	8-K	Financial Statements and Exhibits, Other Events Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 30, 2014 SALIX PHARMACEUTICALS, LTD. (Exact name of registrant as specified in its charter) Delaware 000-23265 94-3267443 (State or other jurisdiction of incorporation)
October 17, 2014	EX-99.1	SALIX PHARMACEUTICALS OUTLINES DATA PRESENTATIONS AT AMERICAN COLLEGE OF GASTROENTEROLOGY 2014 ANNUAL SCIENTIFIC MEETING EX-99.1 4 d806664dex991.htm EX-99.1 Exhibit 99.1 Contact: Adam C. Derbyshire G. Michael Freeman Executive Vice President and Chief Financial Officer Associate Vice President, Investor Relations and Corporate Communications 919-862-1000 919-862-1000 SALIX PHARMACEUTICALS OUTLINES DATA PRESENTATIONS AT AMERICAN COLLEGE OF GASTROENTEROLOGY 2014 ANNUAL SCIENTIFIC MEETING RALEIGH, NC, October 17, 2014
October 17, 2014	EX-10.1	Amendment Number Three to Supply Agreement dated July 30, 2014 between Salix Pharmaceuticals, Inc. and Alfa Wassermann, S.p.A., originally filed as Exhibit 10.1 to Salix’s Current Report on Form 8-K filed on October 17, 2014, which is incorporated by reference herein. EX-10.1 CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. Exhibit 10.1 Execution Version AMENDMENT NUMBER THREE TO SUPPLY AGREEMENT This Amendment Number Three to Supply Agreement (this “Amendment”), dated July 30, 2014 (the “Am
October 17, 2014	EX-10.1	Amendment Number Three to Supply Agreement dated July 30, 2014 between Salix Pharmaceuticals, Inc. and Alfa Wassermann, S.p.A., originally filed as Exhibit 10.1 to Salix’s Current Report on Form 8-K filed on October 17, 2014, which is incorporated by reference herein. EX-10.1 CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. Exhibit 10.1 Execution Version AMENDMENT NUMBER THREE TO SUPPLY AGREEMENT This Amendment Number Three to Supply Agreement (this “Amendment”), dated July 30, 2014 (the “Am
October 17, 2014	EX-10.2	Amendment Number Four to Supply Agreement dated September 4, 2014 between Salix Pharmaceuticals, Inc. and Alfa Wassermann, S.p.A., originally filed as Exhibit 10.2 to Salix’s Current Report on Form 8-K filed on October 17, 2014, which is incorporated by reference herein. EX-10.2 CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. Exhibit 10.2 Execution Version AMENDMENT NUMBER FOUR TO SUPPLY AGREEMENT This Amendment Number Four to Supply Agreement (this “Amendment”), dated September 4th, 2014 (the
October 17, 2014	EX-10.2	Amendment Number Four to Supply Agreement dated September 4, 2014 between Salix Pharmaceuticals, Inc. and Alfa Wassermann, S.p.A., originally filed as Exhibit 10.2 to Salix’s Current Report on Form 8-K filed on October 17, 2014, which is incorporated by reference herein. EX-10.2 CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. Exhibit 10.2 Execution Version AMENDMENT NUMBER FOUR TO SUPPLY AGREEMENT This Amendment Number Four to Supply Agreement (this “Amendment”), dated September 4th, 2014 (the
October 8, 2014	8-K	Financial Statements and Exhibits, Other Events Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 8, 2014 SALIX PHARMACEUTICALS, LTD. (Exact name of registrant as specified in its charter) Delaware 000-23265 94-3267443 (State or other jurisdiction of incorporation
October 8, 2014	EX-99.1	FDA Approves UCERIS® (Budesonide) 2mg Rectal Foam for the Induction of Remission of Mild-to-Moderate Distal Ulcerative Colitis Field Promotion to Launch January 2015 EX-99.1 2 d801922dex991.htm EX-99.1 Exhibit 99.1 Contact: Adam C. Derbyshire G. Michael Freeman Executive Vice President Associate Vice President, Investor Relations and Chief Financial Officer and Corporate Communications 919-862-1000 919-862-1000 FDA Approves UCERIS® (Budesonide) 2mg Rectal Foam for the Induction of Remission of Mild-to-Moderate Distal Ulcerative Colitis Field Promotion to Launc
October 6, 2014	8-K	Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits, Other Events Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 2, 2014 SALIX PHARMACEUTICALS, LTD. (Exact name of registrant as specified in its charter) Delaware 000-23265 94-3267443 (State or other jurisdiction of incorporation
October 6, 2014	EX-10.1	TERMINATION AGREEMENT EX-10.1 EXHIBIT 10.1 TERMINATION AGREEMENT This TERMINATION AGREEMENT (this “Agreement”), dated as of October 2, 2014, is made and entered into by and among Salix Pharmaceuticals, Ltd., a Delaware corporation (“Salix”), Cosmo Pharmaceuticals S.p.A., an Italian public corporation (società per azioni) (“Cosmo”), Cosmo Technologies Limited, a private limited company organized under the laws of Irelan
October 6, 2014	EX-99.1	Salix Pharmaceuticals and Cosmo Technologies Announce Termination of Merger Agreement EX-99.1 3 d800020dex991.htm EX-99.1 EXHIBIT 99.1 Salix Contacts: Adam C. Derbyshire G. Michael Freeman Executive Vice President Associate Vice President, Investor Relations and Chief Financial Officer and Corporate Communications 919-862-1000 919-862-1000 Cosmo Contact: Dr. Chris Tanner CFO and Head of Investor Relations Tel: + 0041 79 401 36 79 Salix Pharmaceuticals and Cosmo Technologies Announc
September 30, 2014	8-K	Financial Statements and Exhibits, Other Events Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 29, 2014 SALIX PHARMACEUTICALS, LTD. (Exact name of registrant as specified in its charter) Delaware 000-23265 94-3267443 (State or other jurisdiction of incorporat
September 30, 2014	EX-99.1	FDA Approves RELISTOR® Subcutaneous Injection for the Treatment of Opioid-Induced Constipation in Patients with Chronic Non-cancer Pain Marketing Approval Expands Treatment to Include Nearly 11 Million Patients Who Experience Opioid-Induced Constipat EX-99.1 Exhibit 99.1 Salix Contact: Adam C. Derbyshire G. Michael Freeman Executive Vice President Associate Vice President, Investor Relations and Chief Financial Officer and Corporate Communications 919-862-1000 919-862-1000 Progenics Contact: Melissa Downs Investor Relations Manager 914-789-2800 FDA Approves RELISTOR® Subcutaneous Injection for the Treatment of Opioid-Induced Constipation in Pa
September 22, 2014	EX-10.1	SETTLEMENT AGREEMENT EX-10.1 2 d790398dex101.htm EX-10.1 Exhibit 10.1 SETTLEMENT AGREEMENT This SETTLEMENT AGREEMENT (the “Settlement Agreement”) is hereby entered into and made effective on September 22, 2014 (the “Effective Date”) by and among: SANTARUS, INC., a corporation organized and existing under the laws of Delaware having a principal place of business at 8510 Colonnade Center Drive, Raleigh, North Carolina 2
September 22, 2014	EX-10.1	SETTLEMENT AGREEMENT EX-10.1 2 d790398dex101.htm EX-10.1 Exhibit 10.1 SETTLEMENT AGREEMENT This SETTLEMENT AGREEMENT (the “Settlement Agreement”) is hereby entered into and made effective on September 22, 2014 (the “Effective Date”) by and among: SANTARUS, INC., a corporation organized and existing under the laws of Delaware having a principal place of business at 8510 Colonnade Center Drive, Raleigh, North Carolina 2
September 22, 2014	EX-99.1	Salix Announces FDA User Fee Goal Date of February 28, 2015 for XIFAXAN® 550mg sNDA for Treatment of Irritable Bowel Syndrome with Diarrhea Results of XIFAXAN® 550mg TARGET 3 Study Selected by American College of Gastroenterology for Oral Presentatio EX-99.1 Exhibit 99.1 Contact: Adam C. Derbyshire G. Michael Freeman Executive Vice President Associate Vice President, Investor Relations and Chief Financial Officer and Corporate Communications 919-862-1000 919-862-1000 Salix Announces FDA User Fee Goal Date of February 28, 2015 for XIFAXAN® 550mg sNDA for Treatment of Irritable Bowel Syndrome with Diarrhea Results of XIFAXAN® 550mg TARGET 3 Stud
September 22, 2014	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 18, 2014 SALIX PHARMACEUTICALS, LTD. (Exact name of registrant as specified in its charter) Delaware 000-23265 94-3267443 (State or other jurisdiction of incorporation)
September 18, 2014	EX-99.1	SALIX SECURES ADDITIONAL INTELLECTUAL PROPERTY RELATING TO RIFAXIMIN EX-99.1 Exhibit 99.1 Contact: Adam C. Derbyshire G. Michael Freeman Executive Vice President Associate Vice President, Investor Relations and Chief Financial Officer and Corporate Communications 919-862-1000 919-862-1000 SALIX SECURES ADDITIONAL INTELLECTUAL PROPERTY RELATING TO RIFAXIMIN RALEIGH, NC, September 18, 2014 - Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that Cipla Limited
September 18, 2014	8-K	Financial Statements and Exhibits, Other Events Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 18, 2014 SALIX PHARMACEUTICALS, LTD. (Exact name of registrant as specified in its charter) Delaware 000-23265 94-3267443 (State or other jurisdiction of incorporat
September 16, 2014	EX-99.1	UCERIS® (budesonide) 2mg Rectal Foam for the Induction of Remission of Mild-to-Moderate Distal Ulcerative Colitis Granted Tentative Approval by FDA EX-99.1 Exhibit 99.1 Salix Contact: Adam C. Derbyshire G. Michael Freeman Executive Vice President and Chief Financial Officer Associate Vice President, Investor Relations and Corporate Communications 919-862-1000 919-862-1000 UCERIS® (budesonide) 2mg Rectal Foam for the Induction of Remission of Mild-to-Moderate Distal Ulcerative Colitis Granted Tentative Approval by FDA RALEIGH, NC, September 15
September 16, 2014	8-K	Financial Statements and Exhibits, Other Events Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 15, 2014 SALIX PHARMACEUTICALS, LTD. (Exact name of registrant as specified in its charter) Delaware 000-23265 94-3267443 (State or other jurisdiction of incorporat
September 2, 2014	EX-99.1	Salix Submits Response to XIFAXAN® 550mg Complete Response Letter Regarding Repeat Treatment for Irritable Bowel Syndrome with Diarrhea EX-99.1 Exhibit 99.1 Salix Contact: Adam C. Derbyshire Executive Vice President and Chief Financial Officer 919-862-1000 G. Michael Freeman Associate Vice President, Investor Relations and Corporate Communications 919-862-1000 Salix Submits Response to XIFAXAN® 550mg Complete Response Letter Regarding Repeat Treatment for Irritable Bowel Syndrome with Diarrhea RALEIGH, NC, September 2, 2014 – Sali
September 2, 2014	8-K	Financial Statements and Exhibits, Other Events Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 2, 2014 SALIX PHARMACEUTICALS, LTD. (Exact name of registrant as specified in its charter) Delaware 000-23265 94-3267443 (State or other jurisdiction of incorporati
September 2, 2014	EX-99.1	Salix Submits Response to XIFAXAN® 550mg Complete Response Letter Regarding Repeat Treatment for Irritable Bowel Syndrome with Diarrhea EX-99.1 Exhibit 99.1 Salix Contact: Adam C. Derbyshire Executive Vice President and Chief Financial Officer 919-862-1000 G. Michael Freeman Associate Vice President, Investor Relations and Corporate Communications 919-862-1000 Salix Submits Response to XIFAXAN® 550mg Complete Response Letter Regarding Repeat Treatment for Irritable Bowel Syndrome with Diarrhea RALEIGH, NC, September 2, 2014 – Sali
September 2, 2014	EX-99.1	Salix Submits Response to XIFAXAN® 550mg Complete Response Letter Regarding Repeat Treatment for Irritable Bowel Syndrome with Diarrhea EX-99.1 Exhibit 99.1 Salix Contact: Adam C. Derbyshire Executive Vice President and Chief Financial Officer 919-862-1000 G. Michael Freeman Associate Vice President, Investor Relations and Corporate Communications 919-862-1000 Salix Submits Response to XIFAXAN® 550mg Complete Response Letter Regarding Repeat Treatment for Irritable Bowel Syndrome with Diarrhea RALEIGH, NC, September 2, 2014 – Sali
September 2, 2014	EX-99.1	Salix Submits Response to XIFAXAN® 550mg Complete Response Letter Regarding Repeat Treatment for Irritable Bowel Syndrome with Diarrhea EX-99.1 Exhibit 99.1 Salix Contact: Adam C. Derbyshire Executive Vice President and Chief Financial Officer 919-862-1000 G. Michael Freeman Associate Vice President, Investor Relations and Corporate Communications 919-862-1000 Salix Submits Response to XIFAXAN® 550mg Complete Response Letter Regarding Repeat Treatment for Irritable Bowel Syndrome with Diarrhea RALEIGH, NC, September 2, 2014 – Sali
September 2, 2014	EX-99.1	Salix Submits Response to XIFAXAN® 550mg Complete Response Letter Regarding Repeat Treatment for Irritable Bowel Syndrome with Diarrhea EX-99.1 Exhibit 99.1 Salix Contact: Adam C. Derbyshire Executive Vice President and Chief Financial Officer 919-862-1000 G. Michael Freeman Associate Vice President, Investor Relations and Corporate Communications 919-862-1000 Salix Submits Response to XIFAXAN® 550mg Complete Response Letter Regarding Repeat Treatment for Irritable Bowel Syndrome with Diarrhea RALEIGH, NC, September 2, 2014 – Sali
September 2, 2014	425	SLXP / Salix Therapeuticals, Inc. 425 - Merger Prospectus - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 2, 2014 SALIX PHARMACEUTICALS, LTD. (Exact name of registrant as specified in its charter) Delaware 000-23265 94-3267443 (State or other jurisdiction of incorporati
September 2, 2014	EX-99.1	Salix Submits Response to XIFAXAN® 550mg Complete Response Letter Regarding Repeat Treatment for Irritable Bowel Syndrome with Diarrhea EX-99.1 Exhibit 99.1 Salix Contact: Adam C. Derbyshire Executive Vice President and Chief Financial Officer 919-862-1000 G. Michael Freeman Associate Vice President, Investor Relations and Corporate Communications 919-862-1000 Salix Submits Response to XIFAXAN® 550mg Complete Response Letter Regarding Repeat Treatment for Irritable Bowel Syndrome with Diarrhea RALEIGH, NC, September 2, 2014 – Sali
August 26, 2014	425	SLXP / Salix Therapeuticals, Inc. 425 - Merger Prospectus - 425 425 Filed by Salix Pharmaceuticals, Ltd. Pursuant to Rule 425 of the Securities Act of 1933, and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Salix Pharmaceuticals, Ltd. (Commission File No.: 000-23265) Cosmo Technologies Limited Transaction Question and Answer Document Salix Employees The following questions and answers are for use by leaders, manag
August 19, 2014	EX-99.1	Salix Announces Early Termination of HSR Waiting Period for Pending Transaction EX-99.1 Exhibit 99.1 Salix Contacts: Adam C. Derbyshire G. Michael Freeman Executive Vice President Associate Vice President, Investor Relations and Chief Financial Officer and Corporate Communications 919-862-1000 919-862-1000 Cosmo Contact: Dr. Chris Tanner CFO and Head of Investor Relations Tel: + 0041 79 401 36 79 Salix Announces Early Termination of HSR Waiting Period for Pending Transaction
August 19, 2014	EX-99.1	Salix Announces Early Termination of HSR Waiting Period for Pending Transaction EX-99.1 Exhibit 99.1 Salix Contacts: Adam C. Derbyshire G. Michael Freeman Executive Vice President Associate Vice President, Investor Relations and Chief Financial Officer and Corporate Communications 919-862-1000 919-862-1000 Cosmo Contact: Dr. Chris Tanner CFO and Head of Investor Relations Tel: + 0041 79 401 36 79 Salix Announces Early Termination of HSR Waiting Period for Pending Transaction
August 19, 2014	EX-99.1	Salix Announces Early Termination of HSR Waiting Period for Pending Transaction EX-99.1 Exhibit 99.1 Salix Contacts: Adam C. Derbyshire G. Michael Freeman Executive Vice President Associate Vice President, Investor Relations and Chief Financial Officer and Corporate Communications 919-862-1000 919-862-1000 Cosmo Contact: Dr. Chris Tanner CFO and Head of Investor Relations Tel: + 0041 79 401 36 79 Salix Announces Early Termination of HSR Waiting Period for Pending Transaction
August 19, 2014	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 19, 2014 SALIX PHARMACEUTICALS, LTD. (Exact name of registrant as specified in its charter) Delaware 000-23265 94-3267443 (State or other jurisdiction of incorporation) (Commis
August 19, 2014	EX-99.1	Salix Announces Early Termination of HSR Waiting Period for Pending Transaction EX-99.1 Exhibit 99.1 Salix Contacts: Adam C. Derbyshire G. Michael Freeman Executive Vice President Associate Vice President, Investor Relations and Chief Financial Officer and Corporate Communications 919-862-1000 919-862-1000 Cosmo Contact: Dr. Chris Tanner CFO and Head of Investor Relations Tel: + 0041 79 401 36 79 Salix Announces Early Termination of HSR Waiting Period for Pending Transaction
August 19, 2014	EX-99.1	Salix Announces Early Termination of HSR Waiting Period for Pending Transaction EX-99.1 Exhibit 99.1 Salix Contacts: Adam C. Derbyshire G. Michael Freeman Executive Vice President Associate Vice President, Investor Relations and Chief Financial Officer and Corporate Communications 919-862-1000 919-862-1000 Cosmo Contact: Dr. Chris Tanner CFO and Head of Investor Relations Tel: + 0041 79 401 36 79 Salix Announces Early Termination of HSR Waiting Period for Pending Transaction
August 19, 2014	425	SLXP / Salix Therapeuticals, Inc. 425 - Merger Prospectus - FORM 8-K 425 1 d778828d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 19, 2014 SALIX PHARMACEUTICALS, LTD. (Exact name of registrant as specified in its charter) Delaware 000-23265 94-3267443 (State or other jurisdic
August 19, 2014	EX-99.1	Salix Announces Early Termination of HSR Waiting Period for Pending Transaction EX-99.1 Exhibit 99.1 Salix Contacts: Adam C. Derbyshire G. Michael Freeman Executive Vice President Associate Vice President, Investor Relations and Chief Financial Officer and Corporate Communications 919-862-1000 919-862-1000 Cosmo Contact: Dr. Chris Tanner CFO and Head of Investor Relations Tel: + 0041 79 401 36 79 Salix Announces Early Termination of HSR Waiting Period for Pending Transaction
August 18, 2014	SC 13G	SLXP / Salix Therapeuticals, Inc. / Visium Asset Management, LP - SC 13G Passive Investment SC 13G 1 d775425dsc13g.htm SC 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Salix Pharmaceuticals, Ltd. (Name of Issuer) Common Stock, $0.001 per share (Title of Class of Securities) 795435106 (CUSIP Number) August 8, 2014 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pu
August 12, 2014	EX-99.1	FDA Assigns September 29, 2014 Prescription Drug User Fee Act Goal Date for RELISTOR® Subcutaneous Injection sNDA for the Treatment of Opioid-induced Constipation in Patients with Chronic Non-cancer Pain FDA Approval Will Expand Treatment of Opioid-i EX-99.1 Exhibit 99.1 Salix Contact: Adam C. Derbyshire G. Michael Freeman Executive Vice President Associate Vice President, Investor Relations and Chief Financial Officer and Corporate Communications 919-862-1000 919-862-1000 Progenics Contact: Melissa Downs Corporate Development 914-789-2800 FDA Assigns September 29, 2014 Prescription Drug User Fee Act Goal Date for RELISTOR® Subcutaneous Inject
August 12, 2014	EX-99.2	SALIX ANNOUNCES IMPORTANT TOPLINE RESULTS FOR MICROBIOME, CULTURE & SUSCEPTIBILITY, AND KEY SECONDARY EFFICACY RESULTS FOR TARGET 3, RIFAXIMIN IBS-D REPEAT TREATMENT STUDY Most Comprehensive Microbiome Data Set in IBS Patients to Date with More than EX-99.2 3 d773535dex992.htm EX-99.2 Exhibit 99.2 Contact: Adam C. Derbyshire G. Michael Freeman Executive Vice President Associate Vice President, Investor Relations and Chief Financial Officer and Corporate Communications 919-862-1000 919-862-1000 SALIX ANNOUNCES IMPORTANT TOPLINE RESULTS FOR MICROBIOME, CULTURE & SUSCEPTIBILITY, AND KEY SECONDARY EFFICACY RESULTS FOR TARGET 3, RIFAXIMIN IBS-D RE
August 12, 2014	EX-99.2	SALIX ANNOUNCES IMPORTANT TOPLINE RESULTS FOR MICROBIOME, CULTURE & SUSCEPTIBILITY, AND KEY SECONDARY EFFICACY RESULTS FOR TARGET 3, RIFAXIMIN IBS-D REPEAT TREATMENT STUDY Most Comprehensive Microbiome Data Set in IBS Patients to Date with More than EX-99.2 3 d773535dex992.htm EX-99.2 Exhibit 99.2 Contact: Adam C. Derbyshire G. Michael Freeman Executive Vice President Associate Vice President, Investor Relations and Chief Financial Officer and Corporate Communications 919-862-1000 919-862-1000 SALIX ANNOUNCES IMPORTANT TOPLINE RESULTS FOR MICROBIOME, CULTURE & SUSCEPTIBILITY, AND KEY SECONDARY EFFICACY RESULTS FOR TARGET 3, RIFAXIMIN IBS-D RE
August 12, 2014	EX-99.2	SALIX ANNOUNCES IMPORTANT TOPLINE RESULTS FOR MICROBIOME, CULTURE & SUSCEPTIBILITY, AND KEY SECONDARY EFFICACY RESULTS FOR TARGET 3, RIFAXIMIN IBS-D REPEAT TREATMENT STUDY Most Comprehensive Microbiome Data Set in IBS Patients to Date with More than EX-99.2 3 d773535dex992.htm EX-99.2 Exhibit 99.2 Contact: Adam C. Derbyshire G. Michael Freeman Executive Vice President Associate Vice President, Investor Relations and Chief Financial Officer and Corporate Communications 919-862-1000 919-862-1000 SALIX ANNOUNCES IMPORTANT TOPLINE RESULTS FOR MICROBIOME, CULTURE & SUSCEPTIBILITY, AND KEY SECONDARY EFFICACY RESULTS FOR TARGET 3, RIFAXIMIN IBS-D RE
August 12, 2014	EX-99.2	SALIX ANNOUNCES IMPORTANT TOPLINE RESULTS FOR MICROBIOME, CULTURE & SUSCEPTIBILITY, AND KEY SECONDARY EFFICACY RESULTS FOR TARGET 3, RIFAXIMIN IBS-D REPEAT TREATMENT STUDY Most Comprehensive Microbiome Data Set in IBS Patients to Date with More than EX-99.2 3 d773535dex992.htm EX-99.2 Exhibit 99.2 Contact: Adam C. Derbyshire G. Michael Freeman Executive Vice President Associate Vice President, Investor Relations and Chief Financial Officer and Corporate Communications 919-862-1000 919-862-1000 SALIX ANNOUNCES IMPORTANT TOPLINE RESULTS FOR MICROBIOME, CULTURE & SUSCEPTIBILITY, AND KEY SECONDARY EFFICACY RESULTS FOR TARGET 3, RIFAXIMIN IBS-D RE
August 12, 2014	8-K	Financial Statements and Exhibits, Other Events Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 11, 2014 SALIX PHARMACEUTICALS, LTD. (Exact name of registrant as specified in its charter) Delaware 000-23265 94-3267443 (State or other jurisdiction of incorporation
August 12, 2014	EX-99.1	FDA Assigns September 29, 2014 Prescription Drug User Fee Act Goal Date for RELISTOR® Subcutaneous Injection sNDA for the Treatment of Opioid-induced Constipation in Patients with Chronic Non-cancer Pain FDA Approval Will Expand Treatment of Opioid-i EX-99.1 Exhibit 99.1 Salix Contact: Adam C. Derbyshire G. Michael Freeman Executive Vice President Associate Vice President, Investor Relations and Chief Financial Officer and Corporate Communications 919-862-1000 919-862-1000 Progenics Contact: Melissa Downs Corporate Development 914-789-2800 FDA Assigns September 29, 2014 Prescription Drug User Fee Act Goal Date for RELISTOR® Subcutaneous Inject
August 12, 2014	EX-99.1	FDA Assigns September 29, 2014 Prescription Drug User Fee Act Goal Date for RELISTOR® Subcutaneous Injection sNDA for the Treatment of Opioid-induced Constipation in Patients with Chronic Non-cancer Pain FDA Approval Will Expand Treatment of Opioid-i EX-99.1 Exhibit 99.1 Salix Contact: Adam C. Derbyshire G. Michael Freeman Executive Vice President Associate Vice President, Investor Relations and Chief Financial Officer and Corporate Communications 919-862-1000 919-862-1000 Progenics Contact: Melissa Downs Corporate Development 914-789-2800 FDA Assigns September 29, 2014 Prescription Drug User Fee Act Goal Date for RELISTOR® Subcutaneous Inject
August 12, 2014	425	SLXP / Salix Therapeuticals, Inc. 425 - Merger Prospectus - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 11, 2014 SALIX PHARMACEUTICALS, LTD. (Exact name of registrant as specified in its charter) Delaware 000-23265 94-3267443 (State or other jurisdiction of incorporation
August 12, 2014	EX-99.2	SALIX ANNOUNCES IMPORTANT TOPLINE RESULTS FOR MICROBIOME, CULTURE & SUSCEPTIBILITY, AND KEY SECONDARY EFFICACY RESULTS FOR TARGET 3, RIFAXIMIN IBS-D REPEAT TREATMENT STUDY Most Comprehensive Microbiome Data Set in IBS Patients to Date with More than EX-99.2 3 d773535dex992.htm EX-99.2 Exhibit 99.2 Contact: Adam C. Derbyshire G. Michael Freeman Executive Vice President Associate Vice President, Investor Relations and Chief Financial Officer and Corporate Communications 919-862-1000 919-862-1000 SALIX ANNOUNCES IMPORTANT TOPLINE RESULTS FOR MICROBIOME, CULTURE & SUSCEPTIBILITY, AND KEY SECONDARY EFFICACY RESULTS FOR TARGET 3, RIFAXIMIN IBS-D RE
August 12, 2014	EX-99.1	FDA Assigns September 29, 2014 Prescription Drug User Fee Act Goal Date for RELISTOR® Subcutaneous Injection sNDA for the Treatment of Opioid-induced Constipation in Patients with Chronic Non-cancer Pain FDA Approval Will Expand Treatment of Opioid-i Exhibit 99.1 Salix Contact: Adam C. Derbyshire G. Michael Freeman Executive Vice President Associate Vice President, Investor Relations and Chief Financial Officer and Corporate Communications 919-862-1000 919-862-1000 Progenics Contact: Melissa Downs Corporate Development 914-789-2800 FDA Assigns September 29, 2014 Prescription Drug User Fee Act Goal Date for RELISTOR® Subcutaneous Injection sNDA
August 12, 2014	EX-99.1	FDA Assigns September 29, 2014 Prescription Drug User Fee Act Goal Date for RELISTOR® Subcutaneous Injection sNDA for the Treatment of Opioid-induced Constipation in Patients with Chronic Non-cancer Pain FDA Approval Will Expand Treatment of Opioid-i Exhibit 99.1 Salix Contact: Adam C. Derbyshire G. Michael Freeman Executive Vice President Associate Vice President, Investor Relations and Chief Financial Officer and Corporate Communications 919-862-1000 919-862-1000 Progenics Contact: Melissa Downs Corporate Development 914-789-2800 FDA Assigns September 29, 2014 Prescription Drug User Fee Act Goal Date for RELISTOR® Subcutaneous Injection sNDA
August 12, 2014	EX-99.1	FDA Assigns September 29, 2014 Prescription Drug User Fee Act Goal Date for RELISTOR® Subcutaneous Injection sNDA for the Treatment of Opioid-induced Constipation in Patients with Chronic Non-cancer Pain FDA Approval Will Expand Treatment of Opioid-i Exhibit 99.1 Salix Contact: Adam C. Derbyshire G. Michael Freeman Executive Vice President Associate Vice President, Investor Relations and Chief Financial Officer and Corporate Communications 919-862-1000 919-862-1000 Progenics Contact: Melissa Downs Corporate Development 914-789-2800 FDA Assigns September 29, 2014 Prescription Drug User Fee Act Goal Date for RELISTOR® Subcutaneous Injection sNDA
August 12, 2014	EX-99.2	SALIX ANNOUNCES IMPORTANT TOPLINE RESULTS FOR MICROBIOME, CULTURE & SUSCEPTIBILITY, AND KEY SECONDARY EFFICACY RESULTS FOR TARGET 3, RIFAXIMIN IBS-D REPEAT TREATMENT STUDY Most Comprehensive Microbiome Data Set in IBS Patients to Date with More than EX-99.2 3 d773535dex992.htm EX-99.2 Exhibit 99.2 Contact: Adam C. Derbyshire G. Michael Freeman Executive Vice President Associate Vice President, Investor Relations and Chief Financial Officer and Corporate Communications 919-862-1000 919-862-1000 SALIX ANNOUNCES IMPORTANT TOPLINE RESULTS FOR MICROBIOME, CULTURE & SUSCEPTIBILITY, AND KEY SECONDARY EFFICACY RESULTS FOR TARGET 3, RIFAXIMIN IBS-D RE
August 11, 2014	425	SLXP / Salix Therapeuticals, Inc. 425 - Merger Prospectus - 425 Filed by Salix Pharmaceuticals, Ltd. Pursuant to Rule 425 of the Securities Act of 1933, and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Salix Pharmaceuticals, Ltd. (Commission File No.: 000-23265) The following is the transcript of the second quarter 2014 earnings conference call of Salix Pharmaceuticals, Ltd.: Operator: Please stand by, we’re abou
August 8, 2014	EX-3.1	SECOND CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION SALIX PHARMACEUTICALS, LTD. June 20, 2014 EX-3..1 Exhibit 3.1 SECOND CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF SALIX PHARMACEUTICALS, LTD. June 20, 2014 Pursuant to Section 242 of the General Corporation Law of the State of Delaware, Salix Pharmaceuticals, Ltd., a corporation organized and existing under the General Corporation Law of the State of Delaware, does hereby certify and set forth as fo
August 8, 2014	EX-10.8	COMMERCIALIZATION AGREEMENT EX-10.8 Exhibit 10.8 CERTAIN MATERIAL (INDICATED BY [***]) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITES AND EXCHANGE COMMISSION. COMMERCIALIZATION AGREEMENT This COMMERCIALIZATION AGREEMENT (this “Agreement”) is made as of August 22, 2011 (the “Effective Date”), by and between Depomed, Inc.,
August 8, 2014	EX-10.7	AMENDMENT NO. 8 TO MANUFACTURING AND SUPPLY AGREEMENT EX-10.7 4 d728321dex107.htm EX-10.7 Exhibit 10.7 AMENDMENT NO. 8 TO MANUFACTURING AND SUPPLY AGREEMENT THIS AMENDMENT (the “Amendment”) is made effective as of the 15th day of April, 2014 (the “Effective Date”), by and among Santarus, Inc., a Delaware corporation having a principal place of business at 8510 Colonnade Center Drive Raleigh NC 27615 (“Santarus”) and Norwich Pharmaceuticals Inc., a De
August 8, 2014	S-8	As filed with the Securities and Exchange Commission on August 8, 2014 As filed with the Securities and Exchange Commission on August 8, 2014 Registration No.
August 8, 2014	EX-3.1	SECOND CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION SALIX PHARMACEUTICALS, LTD. June 20, 2014 EX-3..1 Exhibit 3.1 SECOND CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF SALIX PHARMACEUTICALS, LTD. June 20, 2014 Pursuant to Section 242 of the General Corporation Law of the State of Delaware, Salix Pharmaceuticals, Ltd., a corporation organized and existing under the General Corporation Law of the State of Delaware, does hereby certify and set forth as fo
August 8, 2014	EX-10.6	MANUFACTURING AND SUPPLY AGREEMENT EX-10.6 Exhibit 10.6 CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. MANUFACTURING AND SUPPLY AGREEMENT THIS MANUFACTURING AND SUPPLY AGREEMENT (the “AGREEMENT”) is made effective as of the 27th day of September, 2004 (the “EF
August 8, 2014	EX-10.8	COMMERCIALIZATION AGREEMENT EX-10.8 Exhibit 10.8 CERTAIN MATERIAL (INDICATED BY [***]) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITES AND EXCHANGE COMMISSION. COMMERCIALIZATION AGREEMENT This COMMERCIALIZATION AGREEMENT (this “Agreement”) is made as of August 22, 2011 (the “Effective Date”), by and between Depomed, Inc.,
August 8, 2014	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
August 8, 2014	EX-10.6	MANUFACTURING AND SUPPLY AGREEMENT EX-10.6 Exhibit 10.6 CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. MANUFACTURING AND SUPPLY AGREEMENT THIS MANUFACTURING AND SUPPLY AGREEMENT (the “AGREEMENT”) is made effective as of the 27th day of September, 2004 (the “EF
August 8, 2014	EX-10.7	AMENDMENT NO. 8 TO MANUFACTURING AND SUPPLY AGREEMENT EX-10.7 4 d728321dex107.htm EX-10.7 Exhibit 10.7 AMENDMENT NO. 8 TO MANUFACTURING AND SUPPLY AGREEMENT THIS AMENDMENT (the “Amendment”) is made effective as of the 15th day of April, 2014 (the “Effective Date”), by and among Santarus, Inc., a Delaware corporation having a principal place of business at 8510 Colonnade Center Drive Raleigh NC 27615 (“Santarus”) and Norwich Pharmaceuticals Inc., a De
August 7, 2014	EX-99.1	Salix Pharmaceuticals Reports 2Q2014 Results 2Q14 Total Net Product Revenue Increases 62% Year-over-Year to $382 million 2Q14 EBTIDA Increases 88% Year-over-Year to $155 million 2Q14 XIFAXAN®550 Prescriptions Increase 23% Year-over-Year and 10% vs. 1 EX-99.1 Exhibit 99.1 Contact: Adam C. Derbyshire G. Michael Freeman Executive Vice President Associate Vice President, Investor Relations and Chief Financial Officer and Corporate Communications 919-862-1000 919-862-1000 Salix Pharmaceuticals Reports 2Q2014 Results 2Q14 Total Net Product Revenue Increases 62% Year-over-Year to $382 million 2Q14 EBTIDA Increases 88% Year-over-Year to $155 million 2
August 7, 2014	425	Salix Pharmaceuticals Reports 2Q2014 Results 2Q14 Total Net Product Revenue Increases 62% Year-over-Year to $382 million 2Q14 EBTIDA Increases 88% Year-over-Year to $155 million 2Q14 XIFAXAN®550 Prescriptions Increase 23% Year-over-Year and 10% vs. 1 425 1 d771236d425.htm 425 Filed by Salix Pharmaceuticals, Ltd. Pursuant to Rule 425 of the Securities Act of 1933, and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Salix Pharmaceuticals, Ltd. (Commission File No.: 000-23265) Contact: Adam C. Derbyshire G. Michael Freeman Executive Vice President Associate Vice President, Investor Relations and Chief
August 7, 2014	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 7, 2014 SALIX PHARMACEUTICALS, LTD. (Exact name of registrant as specified in its charter) Delaware 000-23265 94-3267443 (State or other jurisdiction of incorporation) (Com
July 24, 2014	EX-99.1	SALIX PHARMACEUTICALS ANNOUNCES 2Q2014 FINANCIAL RESULTS CONFERENCE CALL AND WEBCAST EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Contact: Adam C. Derbyshire G. Michael Freeman Executive Vice President and Chief Financial Officer Associate Vice President, Investor Relations and Corporate Communications 919-862-1000 919-862-1000 SALIX PHARMACEUTICALS ANNOUNCES 2Q2014 FINANCIAL RESULTS CONFERENCE CALL AND WEBCAST RALEIGH, NC, July 24, 2014 - Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) t
July 24, 2014	EX-99.1	SALIX PHARMACEUTICALS ANNOUNCES 2Q2014 FINANCIAL RESULTS CONFERENCE CALL AND WEBCAST EX-99.1 2 d762877dex991.htm EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Contact: Adam C. Derbyshire G. Michael Freeman Executive Vice President and Chief Financial Officer Associate Vice President, Investor Relations and Corporate Communications 919-862-1000 919-862-1000 SALIX PHARMACEUTICALS ANNOUNCES 2Q2014 FINANCIAL RESULTS CONFERENCE CALL AND WEBCAST RALEIGH, NC, July 24, 2014 - Salix Pharmaceu
July 24, 2014	425	SLXP / Salix Therapeuticals, Inc. 425 - Merger Prospectus - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 24, 2014 SALIX PHARMACEUTICALS, LTD. (Exact name of registrant as specified in its charter) Delaware 000-23265 94-3267443 (State or other jurisdiction of incorporation)
July 24, 2014	8-K	Financial Statements and Exhibits, Other Events Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 24, 2014 SALIX PHARMACEUTICALS, LTD. (Exact name of registrant as specified in its charter) Delaware 000-23265 94-3267443 (State or other jurisdiction of incorporation)
July 17, 2014	425	SLXP / Salix Therapeuticals, Inc. 425 - Merger Prospectus - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 17, 2014 SALIX PHARMACEUTICALS, LTD. (Exact name of registrant as specified in its charter) Delaware 000-23265 94-3267443 (State or other jurisdiction of incorporation)
July 17, 2014	EX-99.1	SALIX AND PHARMING ANNOUNCE FDA APPROVAL OF RUCONEST® FOR THE TREATMENT OF ACUTE ANGIOEDEMA ATTACKS IN PATIENTS WITH HEREDITARY ANGIOEDEMA (HAE) RUCONEST® (C1 ESTERASE INHIBITOR [RECOMBINANT]) 50 IU/kg IS THE FIRST AND ONLY RECOMBINANT TREATMENT OPTI EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Salix Contact: Adam C. Derbyshire G. Michael Freeman Executive Vice President and Chief Financial Officer Associate Vice President, Investor Relations and Corporate Communications 919-862-1000 919-862-1000 SALIX AND PHARMING ANNOUNCE FDA APPROVAL OF RUCONEST® FOR THE TREATMENT OF ACUTE ANGIOEDEMA ATTACKS IN PATIENTS WITH HEREDITARY ANGIOEDEMA (HAE) RUCONE
July 17, 2014	8-K	Financial Statements and Exhibits, Other Events Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 17, 2014 SALIX PHARMACEUTICALS, LTD. (Exact name of registrant as specified in its charter) Delaware 000-23265 94-3267443 (State or other jurisdiction of incorporation)
July 17, 2014	EX-99.1	SALIX AND PHARMING ANNOUNCE FDA APPROVAL OF RUCONEST® FOR THE TREATMENT OF ACUTE ANGIOEDEMA ATTACKS IN PATIENTS WITH HEREDITARY ANGIOEDEMA (HAE) RUCONEST® (C1 ESTERASE INHIBITOR [RECOMBINANT]) 50 IU/kg IS THE FIRST AND ONLY RECOMBINANT TREATMENT OPTI EX-99.1 2 d760489dex991.htm EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Salix Contact: Adam C. Derbyshire G. Michael Freeman Executive Vice President and Chief Financial Officer Associate Vice President, Investor Relations and Corporate Communications 919-862-1000 919-862-1000 SALIX AND PHARMING ANNOUNCE FDA APPROVAL OF RUCONEST® FOR THE TREATMENT OF ACUTE ANGIOEDEMA ATTACKS IN PATIENTS WITH HEREDI
July 16, 2014	425	SLXP / Salix Therapeuticals, Inc. 425 - Merger Prospectus - FORM 8-K AMENDMENT 425 1 d758517d8ka.htm FORM 8-K AMENDMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 14, 2014 SALIX PHARMACEUTICALS, LTD. (Exact name of registrant as specified in its charter) Delaware 000-23265 94-3267443 (State or oth
July 16, 2014	EX-99.1	FDA Office of Drug Evaluation III Approves Salix’s Request that the FDA Approve the RELISTOR® Subcutaneous Injection sNDA for the Treatment of Opioid-induced Constipation in Patients with Chronic Non-cancer Pain Post-marketing Observations Cohort Stu EX-99.1 2 d758517dex991.htm EX-99.1 Exhibit 99.1 Salix Contact: Adam C. Derbyshire G. Michael Freeman Executive Vice President Associate Vice President, Investor Relations and Chief Financial Officer and Corporate Communications 919-862-1000 919-862-1000 Progenics Contact: Melissa Downs Corporate Development 914-789-2800 FDA Office of Drug Evaluation III Approves Salix’s Request that the FDA Appro
July 16, 2014	EX-99.1	FDA Office of Drug Evaluation III Approves Salix’s Request that the FDA Approve the RELISTOR® Subcutaneous Injection sNDA for the Treatment of Opioid-induced Constipation in Patients with Chronic Non-cancer Pain Post-marketing Observations Cohort Stu EX-99.1 Exhibit 99.1 Salix Contact: Adam C. Derbyshire G. Michael Freeman Executive Vice President Associate Vice President, Investor Relations and Chief Financial Officer and Corporate Communications 919-862-1000 919-862-1000 Progenics Contact: Melissa Downs Corporate Development 914-789-2800 FDA Office of Drug Evaluation III Approves Salix’s Request that the FDA Approve the RELISTOR® Subcutaneou
July 16, 2014	EX-99.1	FDA Office of Drug Evaluation III Approves Salix’s Request that the FDA Approve the RELISTOR® Subcutaneous Injection sNDA for the Treatment of Opioid-induced Constipation in Patients with Chronic Non-cancer Pain Post-marketing Observations Cohort Stu EX-99.1 Exhibit 99.1 Salix Contact: Adam C. Derbyshire G. Michael Freeman Executive Vice President Associate Vice President, Investor Relations and Chief Financial Officer and Corporate Communications 919-862-1000 919-862-1000 Progenics Contact: Melissa Downs Corporate Development 914-789-2800 FDA Office of Drug Evaluation III Approves Salix’s Request that the FDA Approve the RELISTOR® Subcutaneou
July 16, 2014	8-K/A	Financial Statements and Exhibits, Other Events Form 8-K Amendment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
July 16, 2014	EX-99.1	FDA Office of Drug Evaluation III Approves Salix’s Request that the FDA Approve the RELISTOR® Subcutaneous Injection sNDA for the Treatment of Opioid-induced Constipation in Patients with Chronic Non-cancer Pain Post-marketing Observations Cohort Stu EX-99.1 Exhibit 99.1 Salix Contact: Adam C. Derbyshire G. Michael Freeman Executive Vice President Associate Vice President, Investor Relations and Chief Financial Officer and Corporate Communications 919-862-1000 919-862-1000 Progenics Contact: Melissa Downs Corporate Development 914-789-2800 FDA Office of Drug Evaluation III Approves Salix’s Request that the FDA Approve the RELISTOR® Subcutaneou
July 16, 2014	EX-99.1	FDA Office of Drug Evaluation III Approves Salix’s Request that the FDA Approve the RELISTOR® Subcutaneous Injection sNDA for the Treatment of Opioid-induced Constipation in Patients with Chronic Non-cancer Pain Post-marketing Observations Cohort Stu EX-99.1 2 d758517dex991.htm EX-99.1 Exhibit 99.1 Salix Contact: Adam C. Derbyshire G. Michael Freeman Executive Vice President Associate Vice President, Investor Relations and Chief Financial Officer and Corporate Communications 919-862-1000 919-862-1000 Progenics Contact: Melissa Downs Corporate Development 914-789-2800 FDA Office of Drug Evaluation III Approves Salix’s Request that the FDA Appro
July 16, 2014	EX-99.1	FDA Office of Drug Evaluation III Approves Salix’s Request that the FDA Approve the RELISTOR® Subcutaneous Injection sNDA for the Treatment of Opioid-induced Constipation in Patients with Chronic Non-cancer Pain Post-marketing Observations Cohort Stu EX-99.1 2 d758517dex991.htm EX-99.1 Exhibit 99.1 Salix Contact: Adam C. Derbyshire G. Michael Freeman Executive Vice President Associate Vice President, Investor Relations and Chief Financial Officer and Corporate Communications 919-862-1000 919-862-1000 Progenics Contact: Melissa Downs Corporate Development 914-789-2800 FDA Office of Drug Evaluation III Approves Salix’s Request that the FDA Appro
July 15, 2014	EX-99.1	FDA Office of Drug Evaluation III Approves Salix’s Request that the FDA Approve the RELISTOR® Subcutaneous Injection sNDA for the Treatment of Opioid-induced Constipation in Patients with Chronic Non-cancer Pain Post-marketing Observations Cohort Stu EX-99.1 Exhibit 99.1 Salix Contact: Adam C. Derbyshire G. Michael Freeman Executive Vice President Associate Vice President, Investor Relations and Chief Financial Officer and Corporate Communications 919-862-1000 919-862-1000 Progenics Contact: Melissa Downs Corporate Development 914-789-2800 FDA Office of Drug Evaluation III Approves Salix’s Request that the FDA Approve the RELISTOR® Subcutaneou
July 15, 2014	EX-99.1	FDA Office of Drug Evaluation III Approves Salix’s Request that the FDA Approve the RELISTOR® Subcutaneous Injection sNDA for the Treatment of Opioid-induced Constipation in Patients with Chronic Non-cancer Pain Post-marketing Observations Cohort Stu EX-99.1 Exhibit 99.1 Salix Contact: Adam C. Derbyshire G. Michael Freeman Executive Vice President Associate Vice President, Investor Relations and Chief Financial Officer and Corporate Communications 919-862-1000 919-862-1000 Progenics Contact: Melissa Downs Corporate Development 914-789-2800 FDA Office of Drug Evaluation III Approves Salix’s Request that the FDA Approve the RELISTOR® Subcutaneou
July 15, 2014	EX-99.1	FDA Office of Drug Evaluation III Approves Salix’s Request that the FDA Approve the RELISTOR® Subcutaneous Injection sNDA for the Treatment of Opioid-induced Constipation in Patients with Chronic Non-cancer Pain Post-marketing Observations Cohort Stu EX-99.1 Exhibit 99.1 Salix Contact: Adam C. Derbyshire G. Michael Freeman Executive Vice President Associate Vice President, Investor Relations and Chief Financial Officer and Corporate Communications 919-862-1000 919-862-1000 Progenics Contact: Melissa Downs Corporate Development 914-789-2800 FDA Office of Drug Evaluation III Approves Salix’s Request that the FDA Approve the RELISTOR® Subcutaneou
July 15, 2014	425	SLXP / Salix Therapeuticals, Inc. 425 - Merger Prospectus - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 14, 2014 SALIX PHARMACEUTICALS, LTD. (Exact name of registrant as specified in its charter) Delaware 000-23265 94-3267443 (State or other jurisdiction of incorporation) (Commissi

SLXP / Salix Therapeuticals, Inc. - Документы SEC, Годовой отчет, Доверенное заявление

Основная статистика

SEC Filings

SEC Filings (Chronological Order)